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1. INTRODUCTION 
 
Thyroid gland is an endocrine gland which is located in anterior aspect of 
neck between cricoid cartilage and suprasternal notch. The two lobes of thyroid 
gland are connected by isthmus. Weight of the gland is 15-20gm. It develops from 
the floor of primitive pharynx at 3rd week along with thyroglossal duct and it 
migrates from floor of tongue to neck. Thyroid hormone synthesis begins at 11th 
week of gestation. Disorders of thyroid gland are very common [1]. 
 
 One of the most important disorders of the thyroid gland is 
hypothyroidism. In adults with hypothyroidism, the onset in usually so insidious 
that typical manifestation take months or years to appear or may go unnoticed. 
The gradual development of the hypothyroid state is the result of slow progression 
of thyroid hypofunction, hypothyroidism continues to be diagnosed at earlier 
stages. Based on the most recent data, subclinical or early hypothyroidism is 
approximately 14 times more common that overt hypothyroidism. Subclinical 
hypothyroidism is seen in children and adolescents. Those who are affected are 
either obese or have family history of thyroid disease. 
 
 Subclinical hypothyroidism is defined as high serum TSH (Thyroid 
stimulating hormone) concentration and normal serum thyroxine and 
triiodothyronine. Considerable controversy exists regarding the definition of a 
high serum TSH concentration, the biologic significance of Subclinical 
hypothyroidism and indication of treatment [2]. 
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 TSH values between 4.2 & 5mU/L are slightly normal. In my study TSH 
level>5.1mIU/L is taken. Subclinical hypothyroidism is more prevalent in patients 
with Down syndrome, type 1 DM (Diabetes mellitus) and other auto immune 
disease. About 2% of pregnant women have Subclinical hypothyroidism. Among 
those pregnant women have, about 58% have positive anti-TPO (Thyroid 
peroxidase). 
 
 In a Michigen outpatient practice 54% patients with Subclinical 
hypothyroidism had chronic autoimmuethyroiditis. In a community survey in 
Whickham England, 67% of women and of 40% men have high serum 
concentration of TSH and TPO. Inadequate thyroid hormone therapy leads to 
overt hypothyroidism. 
 
 Thyroid peroxidise is an enzyme, Microsomal antigen and membrane 
associated glycoprotein. It catalyzes the iodination of tyrosine residues and their 
coupling to form thyroid hormone. TPO-Ab(Thyroid peroxidase antibody)is 
found in serum of auto immune hypothyroidism. It shows high affinity for an 
immune dominant region of TPO moleucules. 
 
 TPO-Abs is positive in 10% of individuals who do not display obvious 
clinical thyroid tissue.100% positive Anti-TPO is seen in patients suffering from 
auto immune hypothyroidism and 80% positive in Graves ‘s disease. 
 
 Anti-Tg (Thyroglobulin) is found in auto immune hypothyroidism, but its 
function is unclear. It is identified by chemiluminescence immune assay. Primary 
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use of TgAb (Thyroglobulin antibody) with serum Tg levels is to differentiate the 
various types of thyroid cancer. 
 
 High TgAb is seen in papillary carcinoma and lymph node metastasis 
[2].Subclinical hypothyroidism is commonly accompanied by dyslipidemia; the 
total cholesterol level is higher and leads to risk of arthrosclerosis.
 “Hypothyroidism facilitates lipid peroxidation, which leads to free radical 
production causing tissue damage” byMarjam et al., 2008 [3]. 
 
 “Dyslipidemia of total cholesterol and low density lipoprotein is seen in 
subclinical hypothyroidism with TSH values >6mu/L” by (Mansourian et 
al.,2008)[3].LDL-cholesterol lipoprotein (a) concentration(Low density 
lipoprotein) is also increased [3].Thyroid hormone reduces the plasma levels of 
Cholesterol, Triglycerides and Phospholipids levels .Reduced hormone increases 
the above mentioned compound levels in plasma leading to atherosclerosis which 
causes deafness and peripheral vascular diseases. Thyroid hormone increases the 
number of LDL receptors in liver cells thereby reducing the plasma LDL levels [1]. 
 
 Ritter,1967 et al Congenital and acquired hypothyroidism are accompanied 
by hearing impairment[4]. Sensorineural hearing loss(SNHL) is the most common 
sensory deficit associated with communication difficulties[4]. 
 
 Pathophysiology of SNHL is immuomediated, Hashimoto’s thyroiditis 
(HT) being, an autoimmune disorder, also leads to hearing dysfunctions[4]. 
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 Hypothyroidism shows elevated concentration of antithyroid antibodies.  
Interaction between genetic susceptibility and environmental factors precipitates 
thyroid autoimmunity. 
 
 The pathophysiology mechanisms of hearing loss in hypothyroid 
individuals are not yet discovered. In this condition, there is reduced cell 
metabolism with reduced microcirculation and this affects metabolism and 
oxygenation of various organs. The striavascularis and organ of corti in the inner 
ear are found be involved. 
 
 Thyroid hormones are concerned with myelin formation and lipid 
concentration in Central nervous system. Thyroxine is a neurotransmitter by itself 
so it is obvious that hearing loss in hypothyroid individuals is of central nervous 
system origin involving the structures of the inner ear[5]. 
 
 Synaptic transmission in auditory pathway is affected by reduced calcium 
absorption in hypothyroidism[5].ATP deficiency causes impaired function of 
sodium –potassium pump .It causes reduced axonal transport in nerve 
fires[5].Increased glycogen and glucosaminoglycans in cell causes the neuropathy 
by compression due to myxeoedematous deposits[5]. 
 
 Conductive type of hearing loss is due to oedema and hypertrophy of 
mucosal lining of Eustachian tube and middle ear .Tympanic membrane is also 
thickened[5]. In hypothyroidism, changes in ossicles in oval and round window 
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cause obliteration of oval and round window, crystallised consistency of bone and 
fusion and distortion of incus[5]. 
 
 Thornton and Jarvis et al evaluated the effect of hypothyroidism on 
auditory pathway by using Brainstem evoked response audiometry(BERA). In 
brainstem evoked response audiometry, stimulus is given to record the electrical 
potential from nervous system by non invasive method. It was done by Dawson 
for the first time in 1947.The evoked response is interpreted by measuring 
amplitudes and latencies in millisecond (ms) domain [5]. 
 
 Brain stem evoked response audiometry is used to detect the auditory 
pathway in brainstem.  Electrodes are kept in vertex and mastoid region. Electrical 
stimulation is given to record the conduction of auditory pathway up to midbrain. 
If sound enters the cochlea, production of electrical impulse passes to the auditory 
cortex by the following pathway: 
 
 First order neuron is bipolar cells of spiral ganglion which end in Ventral 
and Dorsal cochlear nuclei in brainstem. Axons of Second order neurons from 
cochlear nuclei pass in the dorsal part of pons. The crossing fibres of two sides 
form Trapezoid body. Third order neurons have their cell bodies in Superior 
olivary nucleus and Trapezoid body and lateral lemniscus in midbrain .The fibres 
of lateral lemniscus ascend to the mid brain and terminate in the inferior 
colliculus. Fourth order neurons have their cell bodies in inferior colliculus in 
midbrain and fibres arising from this region reach Medial geniculate body in 
Thalamus. Fifth order neurons have their cell bodies in Medial geniculate body 
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and fibres from this region reach form acoustic radiation which ends in 
Auditoryarea in cerebral cortex[6]. 
 
 The normal BERA recordings consists of five or more vertex positive and 
vertex negative waves arising within 10ms (milliseconds) of auditory stimulus. 
Some studies reported the prolongation of both peripheral and central conduction 
time in hypothyroidism. 
 Wave I-Peripheral portion of the VIII nerve 
 Wave II-Cochlear nucleus 
 Wave III-Superior olivary nucleus 
 Wave IV-Lateral Lemniscus 
 Wave V-Inferior colliculus[7]. 
 
Central and peripheral nervous system will be affected in Hypothyroidism[8]. 
 
 Absolute peak latencies of waves I, II, III, IV and V together with IPLs  
I-III, III-V, were recorded. 
 
 In my study by simple non invasive method (BERA)I am going to detect 
central nervous system dysfunction and hearing impairment in earlier stages in 
subclinical hypothyroid patients and evaluate the cause of subclinical 
hypothyroidism by doing anti-TPO and anti-Tg levels and find the correlation of 
BERA with Thyroid antibodies and lipid profiles. 
 
  
Review of literature 
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2. REVIEW OF LITERATURE 
 The thyroid gland is situated below the larynx on either side of and anterior 
to trachea between cricoid cartilage and suprasternal notch which is one of the 
biggest endocrine gland. The thyroid gland secretes THYROXINE (T4) and 
TRIIODOTHYRONINE (T3). Both the hormones increase the basal metabolic 
rate of the body. Thyroid gland secretion is under control of Thyroid stimulating 
hormone (TSH) secreted by anterior pituitary. The thyroid gland also secretes 
calcitonin, a hormone that controls calcium metabolism .The thyroid gland is 
made up of large numbers of closed follicles containing colloid .Thyroid follicles 
are lined with cuboidal epithelial cells that secrete into the interior of the follicles. 
These cells contain numerous granules, endoplasmic reticulum, Golgicomplex and 
lysosome. The colloid contains thyroglobulin molecule. Thyroid hormones are 
present in the colloid. Once the secretion has entered the follicles, it must be 
absorbed back through the follicular epithelium into the blood before it can 
function in the body. The thyroid gland receives blood supply of five times the 
weight of the gland[1]. 
Fig.1 
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2.1 History 
1811 - Bernard Courtosis-discovered iodine 
1907 - David Marine –iodine is necessary for thyroid function 
1909 - Theodor Kocher -Physiology, Pathology and surgery of  
  thyroid gland 
1927 - Thyroxine was synthesized 
1970 - Conversion of Thyroxine to Triiodothyroxine 
1970 - TRH was discovered by Andrew Schally 
1988  - Beta subunit gene for TSH was identified 
1989  - TSH receptor gene was cloned [9] 
 
Fig.2 THYROID CELL 
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Fig.3 THYROID HISTOLOGY[10] 
 
Fig.4 STEPS IN THYROID HORMONE SYNTHESIS[1] 
 
Iodine is needed for formation of Thyroxine. 
 Iodine is absorbed from GIT in the form of Iodide. One year iodine 
requirement is 50mg. One week required amount is 1mg/week. This is the amount 
of iodine needed for normal thyroid function[1]. 
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2.2 SYNTHESIS OF THYROID HORMONE 
1. Iodide trapping 
 Active transport of iodide from circulation into the colloid of thyroid 
follicle (Secondary active transport) occurs. Iodide is transported along with 
sodium.TSH induces expression and retention of Na+/I–symporter in basolateral 
membrane and it leads to continuous iodide uptake. Sodium is pumped into 
interstitium by sodium potassium pump. Resting membrane potential is -50mV in 
thyroid cell.  Iodide is pumped into the cell against electrical gradient. Iodide 
concentration is very high inside the follicular cell. Iodide is going inside the cell 
against chemical gradient. 
 
II. Conversion reaction 
 Iodide is converted into iodine by oxidation. Thyroid peroxidase enzyme is 
needed for this reaction. 
 
III. Thyroglobulin  synthesis 
 Thyroglobulin is a glycoprotein molecule .It contains 2 subunits .Molecular 
weight is 660 kDa. About 123 Tyrosine residues are present in thyroglobulin 
molecule. 
 
 Thyroglobulin molecule is synthesized in endoplasmic reticulum and 
packing occurs in Golgi apparatus and secreted into colloid by exocytosis. 
Thyroid peroxidase enzyme is needed for this reaction. Thyroid hormone is 
produced in the thyroglobulin molecule and present inside the molecule until 
secreted. 
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IV. Organification of thyroglobulin molecule 
 Iodine is bound to tyrosine molecule which is present inside the 
thyroglobulin molecule. This reaction is facilitated by Thyroid peroxidase 
enzyme[11]. 
 
V. Coupling Reaction    
 Iodine binds with tyrosine at 3rd position form monoiodotyrosine. Another 
one molecule is added at 5th position form diiodotyrosine. Two diiodotyrosine 
molecules unite to form thyroxine molecule by oxidative condensation method. 
 
1. Intramolecular coupling  
 Coupling occurs with both diiodotyrosine molecule attached to 
thyroglobulin. 
 
2.  Intermolecular coupling  
 Diiodotyrosine molecule which forms the outer ring is detached from 
thyroglobulin molecule. 
 
 This coupling reaction is facilitated by thyroid peroxidase enzyme. 
 
 One monoiodotyrosine and one diiodotyrosine molecule unite to form 
Triiodothyronine(T3). 
 
 But condensation between diiodotyrosine and monoiodotyroine form 
reverse triiodothyronine (RT3)[10]. 
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VI. Secretion of Thyroid hormones 
 Thyroid follicular cell extends pseudopodia like extensions for uptake of 
colloid by endocytosis to form pinocytic vesicles. Pinocytic vesicle combines with 
lysosomes to form digestive vesicle. It contains protease enzyme that is mixed 
with colloid and digests the thyroglobulin molecule and releases thyroid hormone 
in free form directly into capillaries. 
 
 Some part of iodinated tyrosine in the thyroglobulin molecule never 
becomes thyroid hormone but remains as monoiodotyrosine and diiodotyrosine . 
Enzyme deiodinase cleaves the iodine molecule that is recycled for thyroid 
hormone synthesis again [1].  
 
Fig.5 REGULATION OF THYROID HORMONE SECRETION 
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 Thyroid function is regulated by Thyroid stimulating hormone (TSH).TSH 
secretion is increased by Thyrotropin releasing hormone (TRH) from 
Hypothalamus. Thyroid hormones inhibit both hypothalamus and pituitary.TSH 
secretion is inhibited by stress, increased by cold and decreased by warmth [10]. 
 
Fig.6 MECHANISM OF ACTION OF THYROID HORMONE 
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2.3 PHYSIOLOGICAL EFFECTS OF THYROID HORMONE 
 Most important action of thyroid hormone is stimulation of oxygen 
consumption 
1.Calorigenic action 
 Thyroxine and Triiodothyronine increase oxygen consumption in 
metabolically active tissue. This calorigenic effect is due to utilization of fatty 
acids .Thyroid hormones increase the membrane bound sodium potassium 
ATPase. Thyroid hormone is essential for metabolism of protein present in skin. 
Milk secretion is stimulated by thyroid hormones. 
 
2. Effects on cardiovascular system 
 Peripheral resistance decreased due to cutaneous vasodilation leads to 
sodium and water absorption. Cardiac output, pulse pressure and cardiac rate are 
increased.Triiodothyronine enhances alpha myosin heavy chain, sarcoplasmic 
reticulum Ca2+ ATPase, Beta-adrenergic receptors, G proteins, Na, K ATPase and 
certain K+ channels. Beta-myosin heavy chain, phospholamban, two types of 
adenylyl cyclase, T3 nuclear receptors, and NCX, the Na+–Ca2+ exchanger are 
inhibited by thyroid hormone. 
 
3. Effect on Muscle-It causes protein breakdown. 
 
4. Effects on Bone- Thyroid hormone is needed for growth and skeletal 
development. 
 
5. Effects on Adipose tissue- Lipolysis occurs 
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6. Action on Lipoprotein- it leads to formation of low density lipoprotein (LDL) 
receptors. 
7. Action on Gut- Rate of carbohydrate absorption is increased. 
 
2.4 ACTION OF THYRID HORMONE ON CENTRAL NERVOUS 
SYSTEM 
 Normal development of nervous system depends on thyroid hormone. The 
parts of brain most affected are cerebral cortex, Basal ganglia and Cochlea.  
Mental retardation, motor rigidity, and deaf–mutism occur due to deficiency of 
thyroid hormones during development[10]. 
 
Fig.7 THYROID HORMONE ENTRY INTO CENTRAL NERVOUS 
SYSTEM 
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 MCT8- is a T-type amino acid transporter belonging to the 
monocarboxylate transporter family expressed in the brain, heart, kidney, liver, 
and skeletal muscle. It facilitates transport of T3, T4, rT3 and T2 across cell 
membranes in vitro. It is encoded by X chromosome [12]. 
 
 T4, OATP1C1 (a member of the organic anion transporting polypeptide 
family) is involved in the transport of T4 across the blood-brain barrier. Thyroid 
hormone (TH) is essential for myelination explained by Bernal 2002, 2007, 
Zoeller&Rovet 2004, Darras 2008. 
 
 Synthesis of oligodendrocyte(OL) from multi potent neural stem cells 
depend on thyroid hormone . Development and maturation of OL needs thyroxine. 
TH act as an instructive agent, triggering OPCs (oligodendrocyteprecursorscells) 
cell cycle exit in close cooperation with platelet-derived growth factor (PDGF). T3 
regulates OPC proliferation and differentiation through a mitogen-dependent 
intrinsic cell timer. They become sensitive to T3 after eight cell divisions (or 
corresponding time) because of a cell cycle-dependent expression of TRs 
(Thyroid hormone Receptors). Cellular programming, micro-environmental 
signals and cell cycle are controlled by thyroid hormone. A cell cycle dependent 
balance among the different TR iso forms could regulate the differential hormonal 
sensitivity and thus the transcriptional response to T3 in the different phases of the 
cell cycle which also occurs in mature CNS.  OPCs progress toward myelinating 
OLs stage TRa expression is decreased. Terminal maturation mainly depends on 
TRb1. THs stimulate the morphological and functional maturation of OLs. It is 
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done by thyroid hormones by inducing different genes, like myelin-OL 
glycoprotein, myelin basic protein (MBP) and glutamine synthese. 
 
TH and CNS Remyelination 
 Miller &Mi 2007 et al reported that remyelination is a recapitulation of 
developmental myelination and thyroid hormone has a role in remyelination. 
 
 Schenker et al in 2002 proposed that cytoskeleton protein expression 
during axon growth and regeneration are accelerated by thyroid hormone.  
 
 Berbel et al. 1994, Guadan ˜o Ferraz et al in 1994 expressed that White 
matter growth and organization are controlled by thyroid hormone due to its 
modulator action on axon-OL. 
 
 Trentin 2006 told that astrocyte differentiation and maturation is regulated 
by TH by promoting the production of extracellular matrix proteins and growth 
factors. These proteins are responsible for neuronal growth and neuritogenesis.  
 
 Mendes-de-Aguiar et al in 2008 told that extracellular matrix proteins like 
laminin, ﬁbronectin and syndecan synthesis is altered by T3. 
 
 Process of myelinization via peripheral Schwann cells and central 
oligodendrocytes  were  accelerated by neuronal activity.  
 
Schaeren-Wiemers and Gerﬁn-Moser, 1993, Lees and Brostoff, 1984; Lemke, 
1988, 1995  et al reported that peripheral protein zero (P0) and the myelin basic 
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protein (MBP) were used as marker in the peripheral nervous system and 
proteolipid protein (PLP) and MBP for the central nervous system.  
 
Campagnoni and Hunkeler, in 1980 demonstrated that mRNA of these marker 
appearances corresponds to that of myelination. Peripheral and central myelin 
markers appeared in the intra dural part of the cochlea depends on thyroid 
hormone. In auditory system, the evoked auditory brainstem responses need rapid 
and synchronized activation of neuronal pathways. Moore et al in 1995 told that 
Synchronized conduction depends on myelinogenesis[13]. 
 
2.5 Action on auditory system 
Cochlea is a receptor organ for hearing. Hair cells act as receptors. Primary 
sensory receptors are inner hair cells. They are responsible for production of 
action potential which depends on the movement of fluid. Outer hair cells respond 
to sound in which depolarization causes shortening and hyper polarization 
produces lengthening. Outer hair cells cause amplification of sound waves 
reaching the cochlea. This action is due to changes in membrane protein called 
PRESTIN. This is a motor protein in outer hair cell [10]. 
 
 Voltage-dependent conformational changes of motor proteins that are 
densely packed in the lateral plasma membrane cause electromotility. 
 
 Zheng et al reported that Prestin a putative motor protein was invented by 
cDNA library subtraction procedure. 
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 Outer hair cells (OHCs) have a property to change their length in higher 
frequencies. Also they contain frequency resolving capacity. Prestin is a sulfate 
anion transport protein which is present in outer hair cell. Prestin ATG codon 
contains TH response element in the first intron. PrestinTRE (Thyroid response 
element) binds TH receptors as a monomer or presumptive heterodimer and 
mediated a triiodothyronine-dependent transactivation of a heterologous promotor 
in response to triiodothyronine receptors  and Retinoid X receptor had an additive 
effect. Prestin mRNA and Prestin protein levels are reduced in unavailability of 
thyroid hormone. Immature prestin is present in hypothyroidism. Transcriptional 
regulator of the motor protein prestin is thyroid hormone [14]. 
 
2.6 THYROID FUNCTION TESTS 
Tests for thyroid function come under five headings. 
1. Tests to asses  Hypothalamo-Pituitary –Ovarian axis 
2. Tests to asses Thyroid hormones Levels in blood. 
3. Tests to investigate about thyroid autoimmune disease. 
4. Tests to asses Thyroid iodine metabolism 
5. Tests to investigate about effect of thyroid hormone on tissues. 
 
Examples 
1. Measurment of BMR(Oxygen consumption) 
2. Estimation of protein bound iodine 
3. Radioactive iodine uptake(RAIU) 
4. Serum T3 , T4 , TSH-estimation –best test 
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5. Ultrasonagraphy (B scan) of thyroid gland 
6. Thyroid scan (iodine, Tchnetim99) with radioactive elements 
7. Antithyroid antibodies 
8. FNAC[6] 
 
 Estimation of Thyroid stimulating hormone level is a highly sensitive and 
specific test. It gives information about negative feedback regulation of thyroid 
hormone synthesis. Thyroid hormones control pituitary TSH release.  
 
TABLE NO.1Normal values of Thyroid profile [2] 
TSH 0.4-4.2mIU/ml 
Free T3 0.2-0.5ng/dl 
Free T4 0.7-2.5ng/dl 
Total T3 70-190 ng/dl 
Total T4 5-11µg/dl 
 
2.7 HYPOTHYROIDISM  
 Production of reduced thyroid hormone is known as Hypothyroidism. Any 
destruction or loss of thyroid tissue due to autoimmunity or radiation injury causes 
primary hypothyroidism. Defect in Hypothalamus or pituitary or Thyroid 
stimulating hormone leads to secondary hypothyroidism. Temporary or transient 
hypothyroidism is due to sub acute thyroiditis. Any condition leading to reduced 
thyroid hormone levels causes enlargement of thyroid gland. 
 
 
 
 
21 
 
 Hypothyroidism affects all organs.  Clinical manifestations depend on the 
thyroid hormone levels. ‘Myxedema’ word denotes appearance of the skin and 
subcutaneous tissues in hypothyroid patients. Severe hypothyroidism with this 
clinical picture is rarely seen now days. Myxedema terminology is used to 
describe the clinical signs of Hypothyroidism.         
 
FIG.8. MYXEDEMA AND LOSS OF LATERAL ASPECT OF EYEBROW 
 
 
2.7.1 Changes in Skin and appendages 
 Hypothyroidism causes accumulation of hyaluronic acid and chondroitin 
sulphate in dermis. These substances are bound with protein to form tissue gel, 
which increases the fluid in interstitial space. Due to this gel nature interstitial 
fluid is immobile, so edema is non pitting in nature. 
 
2.7.2 Cardiovascular system 
 Cardiac output is decreased due to decrease in heart rate and stroke 
volume. Blood volume is decreased and peripheral resistance is increased. 
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Peripheral cutaneous circulation is diminished which is responsible for cold skin. 
Heart rate is diminished due to pericardial effusion. Thyroid hormones have an 
effect on angina pectoris and coronary artery disease. Electrocardiographic picture 
shows sinus bradycardia, prolongation of the PR interval, low amplitude of the P 
wave and QRS complex, alterations of the ST segment, and flattened or inverted 
T waves. Echocardiogram reflects resting left ventricular diastolic dysfunction in 
overt, and in some studies, subclinical hypothyroidism. 
 
2.7.3 Respiratory system 
 Pleural effusions, alveolar hypoventilation and carbon dioxide retention  
 
2.7.4 Gastrointestinal system 
 Weight gain (accumulation of fluid in interstitial space due to hydrophilic 
glycoprotein), decreased appetite, Decreased peristalsis activity, Constipation and 
adynamic ileus. 
 
2.7.5 Central and Peripheral nervous system 
 Thyroid gland is needed for growth of brain in early life. Reduced level of 
this hormone causes defect in cortical neurons, myelination and vascularity. If 
damage is not corrected in earlier stage it leads to permanent defect. Speech, 
thought and movement are reduced. Lethargy and sleepiness and delayed 
relaxation of ankle jerk will be present. Entrapment of peripheral nerves by 
ground substance causes carpal tunnel syndrome. 
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2.7.6 Reproductive system 
 Menorrhagia, infertility and galactorrhoea,  
 
2.7.7 Blood - Anemia 
 
2.7.8 Treatment 
 Replacement of thyroid hormone is in the form of L-Thyroxine[2]. 
 
2.8 SUBCLINICAL HYPOTHYROIDISM 
 Subclinical hypothyroidism is a biochemical condition. Thyroxine and 
Triiodothyronine levels are normal but thyroid stimulating hormone level is 
elevated. SCTD (Subclinical thyroid disease) is identified in young, middle and 
old age population. Due to presence of high prevalence it progresses to overt 
hypothyroidism, SCTD is considered as a significant clinical condition. Regarding 
SCTD symptoms and signs are different in each tissue of our body. At which level 
of TSH we have to give treatment is also controversial. The prevalence of SCTD 
is 4-10%. About 20% prevalence is seen in women older than 60 years. The 
various names of SCTD are compensated hypothyroidism, preclinical 
hypothyroidism, mild thyroid failure, and mild hypothyroidism. 
 
 SCTD is a TSH abnormality in which upper limit is not fully explained. It 
is reduced from 10mIU/liter to about 4.0–4.5 mIU/liter by TSH RIAs (Radio 
immune assay) and thyroid antibody tests. 
 
 Now days we are using monoclonal antibodies. It will detect various 
isoforms of TSH.  
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 National Health and Nutritional Examination (NHANES) III survey shows 
10% prevalence of anti thyroglobulin antibody (TgAb) and 12% prevalence of 
detectable thyroid peroxidase (TPO) levels is seen community [15].   
 
 National Academy of Clinical Biochemistry criteria as well as sonographic 
confirmation of a normal thyroid gland study in reference shows, the  reference 
range for the lower limit of TSH increased from 0.3 to 0.4 mIU/liter and 4.1 to 3.7 
mIU/liter is used as higher level [16]. 
 
 Serum TSH of 0.25–2.12 mIU/liter is used as a reference level in iodine -
deficient area (western Pomerania, northeast Germany)[17].  
 
 In iodine deficient village of southern Italy, TSH concentration in the adult 
population was 1.4 ±1.1 mIU/liter in goitrous subjects and 2.0 ±2.4 mIU/liter in 
nongoitrous subjects [18]. 
 
Whickham survey shows that TSH >2mIU/liter has increased chance of 
getting Hypothyroidism. If they are positive for thyroid peroxidase antibody, they 
have more chance of becoming hypothyroid. 
 
 Epidemiological evidence reveals that TSH between 3 and 4.5 mIU/liter 
and those having positive anti thyroid antibodies have increased chance of getting 
hypothyroidism. Additional importance should be given to these persons and 
continuous follow up should be given [19]. 
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 Serum FT4 and TSH are specific for each person. These levels are 
monitored by hypothalamic-pituitary-thyroid axis “set-point [20]. 
 
 Individual variation in hypothalamic-pituitary-thyroid axis set-point 
depends on genetics of particular individuals [21, 22]. 
 
 The action of thyroid hormone depends on presence of T3, it’s level is 
controlled by type 1, 2, and 3 iodotyrosinedeiodinases (D1, D2, and D3).If serum 
T4 level decreased there is increased change of T4 to T 3 by D2 [23].  
 
 Biological activity of thyroid hormone is influenced by polymorphisms in 
genes involved in thyroid hormone metabolism [24]. 
 
 Deiodinase enzyme has tissue specific action, and its level is controlled by 
feedback regulation [25]. 
 
 Subclinical hypothyroidism is classified into two groups .First one has 
TSH level between 4.5 and 10 mIU/liter. Another group has TSH level >10 
mIU/liter[26]. 
 
 The cause of subclinical hypothyroidism is like that of overt 
hypothyroidism [27].  
 
 The most common cause of subclinical hypothyroidism is autoimmune 
disorders of thyroid gland. Examples are goitrous Hashimoto’s thyroiditis and 
atrophic thyroiditis. 
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 Treatment which causes destruction of thyroid tissue like radioactive 
iodine treatment or external radiation therapy produces primary hypothyroidism. 
This frequently occurs if radiation is given over head and neck region and is a 
dose dependent effect [15].  
 
 Chemotherapy is also a cause of hypothyroidism [28]. 
 
 Women with breast cancer have increased risk of developing subclinical 
hypothyroidism. After subacute, postpartum, or painless thyroiditis and partial 
thyroidectomy also can cause subclinical hypothyroidism [29, 30]. 
 
 Subclinical or overt hypothyroidism is caused by drugs like iodine-
containing compounds, lithium carbonate, cytokines, and interferon. Amiodarone 
is prescribed to treat tachyarrhythmias. It stops the thyroid hormone 
production[15]. 
 
 Amiodarone treated persons have an increased risk of Iodine-induced 
subclinical or overt hypothyroidism. Mild or transient hypothyroidism may be 
produced by excess dietary iodine, medication, topical antiseptics and iodine 
contrast agents used for diagnostic procedures [31].  
 
 Manic-depressive disorders are treated by Lithium carbonate. It produces 
goitre and hypothyroidism. These patients also have underlying Hashimoto 
thyroiditis [32, 33]. 
 
 Interferon alfa and IL-2 cause autoimmune thyroiditis [34].  
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 Subclinical hypothyroidism is common in multiple sclerosis patients after 
starting treatment [35]. 
 
 Sunitinib, a drug used to treat gastrointestinal stromal tumour and renal cell 
carcinoma can cause TSH elevation. Increased risk of hypothyroidism is seen in 
Postpartum period. Autoimmune thyroiditis is a part of other endocrine disorders, 
like polyendocrine failure syndrome type I. It contains hypoparathyroidism, 
adrenal insufficiency, and chronic mucocutaneous candidiasis. 
 
 Poly endocrine failure type 2 is a combination of adrenal insufficiency, 
type 1 diabetes mellitus and primary ovarian failure. 
 
 Patients with overt hypothyroidism those who are getting improper 
treatment is a cause for subclinical hypothyroidism. It can also occur due to drug 
interactions or if treatment is not monitored properly [36]. 
 
 Inadequate thyroid hormone supplementation is a reason for subclinical 
hypothyroidism between 17.6 and 30% of patients with overt thyroid failure [37]. 
 
 Genetic mutation in TSH receptor can produce subclinical hypothyroidism 
[38, 39]. 
 
2.8.1 Differential diagnosis of subclinical hypothyroidism 
1. Transient subclinical hypothyroidism following sub acute, painless, or 
postpartum thyroiditis [15] 
2. After withdrawal of thyroid hormone therapy in euthyroid patients [15] 
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3. Laboratory analytical problem (assay variability, heterophilic 
antibodies)[40] 
4. Impaired renal function [15] 
5. Recovery phase of euthyroid sick syndrome [15] 
6. Untreated adrenal insufficiency[41] 
7. TSH-secreting pituitary adenoma [42] 
8. Isolated pituitary resistance to thyroid hormone 
 
 Old age, female sex and TPO antibodies positive with increased TSH 
values are increased risks of having overt hypothyroidism. 
 
If the person has elevated TSH and positive TPO antibodies, chance of 
getting overt hypothyroidism is 4.3%. In women, 3% chance of becoming 
hypothyroid if the person has only elevated TSH. About 2% of persons become 
overt hypothyroid only if anti thyroid antibodies are positive. If serum level of 
TSH is more than 2 mIU/ litre, they have increased risk of becoming overt 
hypothyroidism [19].  
 
 Thyroid auto antibodies were used as a prognostic relevance in elderly 
subjects.  Geriatric patients become overt hypothyroid in a follow up period of 
some years. 
 
 If the TSH value is more than 20mIU/litre, surely they will become overt 
hypothyroid. About 80% of Anti microsomal antibodies positive persons become 
overt hypothyroid irrespective of TSH value [43]. 
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 Pregnant women with asymptomatic autoimmune thyroiditis have 
increased risk to become overt hypothyroid [44]. 
 
2.8.2 Symptoms of subclinical Hypothyroidism 
 A Colorado study which showed 17 thyroid symptoms express a clear 
correlation between the type of symptoms, number and elevated TSH(dry skin, 
poor memory, slow thinking, muscle weakness, fatigue, muscle cramp, cold 
intolerance, puffy eyes, constipation, and hoarseness).  
 
 Of euthyroid persons who had 12.1% of all listed symptoms, about 16.6% 
become overtly hypothyroid and about 13.8% ended up with mild hypothyroidism 
[45, 46]. 
 
 Zulewski et al introduced new clinical score which contains 14 symptoms. 
He revealed good correlation between this score, FT4 and TSH in patients with 
subclinical hypothyroidism [47]. 
 
 Subclinical hypothyroid patients showed an increased prevalence of 
symptoms than euthyroid[15].  
 
 Among subclinical hypothyroid patients, about 83% expressed fatigue and 
about 80% showed weight gain and some persons showed elevated anxiety scores 
[48].  
 
 Impaired memory is also seen in subclinical hypothyroid patients [49]. 
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2.8.3 Cardiovascular dysfunction in subclinical hypothyroidism 
 Prolonged isovolumetric relaxation time and an impaired time to peak 
filling rate were seen in subclinical hypothyroidism. These parameters are used to 
assess left ventricular diastolic function. It is due to reduced levels of 
sarcoplasmic reticulum calcium ATP ase. It causes reduced calcium uptake into 
sarcoplasmic reticulum and there is impaired diastolic relaxation [50-56]. 
 
 The systolic time interval alterations were seen in subclinical hypothyroid 
patients [57, 58]. 
 
Cardiac volumes and systolic performance were changed in subclinical 
hypothyroidism. End diastolic volume was reduced and the Systemic vascular 
resistance was elevated, which leads to reduced cardiac performance [59].  
 
2.8.4 Vascular system and Subclinical hypothyroidism 
 T3 causes vascular smooth-muscle cells relaxation. It reduces systemic 
vascular resistance by tissue thermo genesis and metabolic activity [60, 61] 
. 
 Sub clinical hypothyroidism is associated with hypertension. Increased 
peripheral vascular resistance, increased arterial stiffness, and endothelial 
dysfunction may be the causes of hypertension [62, 63].  
 
 Increased arterial stiffness in subclinical hypothyroidism is identified by 
pulse wave analysis.  Subclinical hypothyroid persons showed an increase in 
diastolic blood pressure and brachial-ankle pulse wave velocity in TSH values of 
6.9 ±0.82 mIU/litre [63]. 
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 Endothelium dependent vasodilatation is impaired in TSH levels 
between4.01and10mIU/litre and also when it is greaterthan10mIU/litre [64]. 
 
 Endothelial dysfunction was due to reduced level of NO availability. Low-
grade chronic inflammation may be a cause for endothelial dysfunction and 
impaired NO availability by a cyclooxygenase(COX-2)-dependent pathway. 
Subclinical hypothyroid patients showed an increased oxidative stress in 
Hashimoto’s thyroiditis [65]. 
 
2.8.5 Subclinical hypothyroidism and neuromuscular dysfunction 
Subclinical hypothyroidism is associated with neuromuscular 
dysfunctions.Impaired glycogenolysis[66, 67] changes in myosin heavy chain 
expression [68]and decreased  mitochondrial activity may be the causes for 
neuromuscular dysfunction[69,70]. 
 
The amplitude of the stapedial reflex is abnormal in subclinical 
hypothyroidism. It gives information about neuromuscular status [71]. 
 
 Distal motor latencies, motor and sensory amplitudes and nerve conduction 
velocities are normal in mild thyroid hormone deficiency [72]. 
 
 Peripheral nerves or brainstem auditory evoked potential is normal in 
subclinical hypothyroidism of short duration [8].  
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2.8.6 Effect of replacement therapy 
 Levothyroxine is used in Hashimoto’s thyroiditis to reduce the size of the 
thyroid gland. 
 
 One study showed that thyroid volume was decreased in 77% of 
Subclinical hypothyroid patients with Hashimoto’s thyroiditis after treatment with 
Levothyroxine therapy [73]. 
 
 Levothyroxine therapy reduces the thyroid peroxidase antibodies and other 
thyroid antibodies in  Hashimoto thyroiditis or idiopathic myxedema 
 
 Levothyroxine treatment can normalize cardiac hemodynamic alterations 
produced by subclinical hypothyroidism [74].  
 
2.8.7 Maternal and Fetal risk in subclinical hypothyroidism 
 Thyroid autoimmunity is a cause for recurrent miscarriage [75, 76 and 77]. 
La Franchi SH et al described that preterm births are seen in 6% of women with 
Subclinical hypothyroidism which increases to 20% in overt disease. Gestational 
hypertension was present in 11% of subclinical hypothyroid and 23% of overt 
hypothyroidism.  
 
 Perinatal mortality occurred in 2.9 of subclinical hypothyroidism and 7% 
in overt hypothyroidism [15]. 
 
 Inadequate levothyroxine treatment was given for 114 primary 
hypothyroidism patients and they showed the following results. 
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TABLE.2 Outcome of inadequate levothyroxine  in pregnancy 
Outcome Subclinical Hypothyroidism Overt Hypothyroidism 
Abortion 71.4% 60% 
Preterm Delivery 7.2% 20% 
Term delivery 21.4% 20% 
 
 If adequate treatment was given, 100% of overt hypothyroidism and 90.5% 
of subclinical hypothyroidism patients had full term delivery and no incidence of 
abortion occurred [15]. 
 
 Fetal brain development and maturation need maternal FT4 [78, 15]. 
 
 In 1969, Man and Jones reported that Children of hypothyroid mothers, 
who were not properly treated, showed reduced IQ [79]. 
 
2.8.8 Subclinical hypothyroidism in elderly 
 Subclinical hypothyroidism is more common in elder population [15]. 
 Autoimmne thyroiditis and treatment of hyperthyroidism are causes for 
subclinical hypothyroidism in older group [80].  
 
In older persons subclinical hypothyroidism is not recognized and it is 
considered that these changes are due to ageing [81, 82]. 
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2.8.9Treatment 
 Subclinical hypothyroidism is a biochemical disorder. Lifelong 
levothyroxine therapy is debatable. Treatment is given for two reasons: 
 
   1) To prevent progression to overt hypothyroidism 
   2) To prevent thyroid hormone deficiency symptoms  
 
 Treatment for subclinical hypothyroidism is not explained clearly [83, 84]. 
 A panel of 13 experts (eight had expertise in thyroid disease, and eight had 
expertise in cardiology, epidemiology, biostatistics, evidence-based medicine, 
health service research, general internal medicine, and clinical nutrition) 
explained treatment for patients with TSH values between 4.5 and 10 mIU/litre 
should be monitored for 6-to12-month.Dyslipidemia was present only in patients 
with TSH values above 10 mIU/ litre. Treatment was given in these patients due 
to high rate of progression to overt hypothyroidism [85].  
 
 The three societies (the American Association of Clinical Endocrinologist, 
The Endocrine Society, and the ATA) recommended routine treatment of patients 
with subclinical hypothyroidism those who had serum TSH levels of 4.5–10 
mIU/litre [86, 87]. 
 
Younger patients should be treated correctly than older patients [88]. 
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2.9THYROGLOBULIN AND THYROID PEROXIDASE ANTIBODY IN   
SUBCLINICAL HYPOTHYROIDISM  
 Anti thyroperoxidase antibody (TPOAbs) and anti thyroglobulin antibody 
(TgAb) are most common auto antibodies which are expressed in patients with 
autoimmune thyroid diseases [89]. 
 
 Thyroglobulin molecule is a 660kDa protein, which is a precursor of 
thyroid hormone [90]. 
 
 Autoantibodies to thyroglobulin molecule and thyroperoxidase molecule 
are present in 10% of healthy individuals. The actions of these antibodies were not 
fully understood [89]. 
 
 Thyroglobulin antibodies do not fix complement or participate in antibody-
dependent cellular cytotoxicity [90].  
 
 Thyroid peroxidase (TPO) is very important for synthesis of thyroid 
hormones [91]. 
 
 TPOAb and TgAb levels were increased in patients with elevated TSH 
values. 
 Thyroid antibodies were more present in a moderate iodine deficiency area 
(MUI45g/liter) (MUI-Median urinary iodine) than an area with mild iodine 
deficiency (MUI 61 g/liter) [89]. 
 
 
 
36 
 
 Of high-iodine diet fed animals almost 100% of genetically susceptible 
animals became TgAb positive. Positive TgAb and positive TPOAb patients 
showed thyroid dysfunction [89]. 
 
 In patients with Hashimoto's thyroiditis, autoantibodies to Thyroglobulin 
antibodies appear in the three important immunoglobulin classes. Pressman et al., 
1957 Korngold, Van Leeuwen&Brener, 1959, Fahey & Goodman, 1960 explained 
that centrifugation, gel diffusion and  column chromatography methods are used 
to separate physically 7S and 19S fractions of serum. Both 19S and 7S antibodies 
were present in three experiments. 
 
 By zone ultracentrifugation, Torrigiani&Roitt (1963) demonstrated that 
macroglobulin class appeared in <1I% of the total antibodies to thyroglobulin.  
 
 With the help of radio immune electrophoresis Fahey & Goodman (1964) 
and Goodman, Exum& Robbins 1964 demonstrated thyroglobulin antibodies. It is 
present in IgG, IgA and IgM classes of antibodies. 
 
 Chronic thyroiditis patients showed the presence of antibodies to 
thyroglobulin in IgG1, IgG2 and IgG3 in serum. It was explained by Terry & 
Fahey (1964) and Lichter (1964). 
 
 Quantitative coprecipitation techniques were used by Torrigiani, 
Roitt&Doniach (1968)to measure the amount of antibodies to thyroglobulin in the 
IgG, IgA and IgM classes.  
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 Thyroid peroxidase is auto-antigen, which is present in thyroid cell surface 
and cytoplasm .Anti-TPO is expressed in serum of autoimmune thyroid disorder 
patients [92]. 
 
 Autoantibodies against TPO are present in 90% of Hashimoto’s thyroiditis 
. Thyroid cell destruction occurs by cytotoxic mechanisms mediated by effector 
cells and/or complement activation. Antibody dependent cytotoxicity in 
Hashimoto’s thyroiditis was first demonstrated by Bogner et al. 
 
 TPO antibodies belong to IgG1 subclass explained by Guo et al. 
 
 Cell surface TPO activates complement. It causes the cell lysis by 
complement –mediated cytotoxicity explained by Blanchin et al. 
 
 Mononuclear cell accumulation is seen in autoimmune thyroiditis. One 
study demonstrated human anti thyroid antibodies against thyroid peroxidase. 
They were isolated from patients who had autoimmune thyroid disease. It caused 
destruction of thyroid cell by peripheral blood mononuclear cell (HL-60 and  
THP-1)by Antibody dependent cytotoxicity. These reactions are due to Fc γ RI 
and Fc γ RII expressed on these cells. 
 
 Flow cytometric analysis was done to compare the binding of human anti-
TPO Abs by their Fc region on HL60, THP-1and PBMCs. 
 
 Important feature of autoimmune thyroid disease is accumulation of the 
thyroid gland with lymphocytes and monocytes / macrophages. 
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 Thyroid dysfunction induction, amplification and progression of 
autoimmune disease by cytotoxic mechanism were done by Anti-TPO. It is 
explained by Weetman AP et al[93] 
 
 Hypothyroidism occurs in Hashimoto’s thyroiditis in iodine deplete 
individuals.  Repletion of iodine in deficiency and increased iodine intake are 
cause for autoimmunity.  
 
 Thyroid autoimmunity is also produced by exposure to environmental 
chemicals and radiation exposure. 
 
 In Cochin study Hypothyroidism prevalence was 3.9% but about 9.4% 
persons had subclinical hypothyroidism and about 53% of subclinical 
hypothyroidism patients showed positive Anti-TPO. 
 
 Large doses of ingested iodine combines with thyroglobulin molecule to 
produces change in stereochemical conformation and leads to loss of antigenic 
epitopes to cause new iodine containing compound. This molecule is presented to 
T or B lymphocytes by antigen presenting cell which causes production of 
autoimmunity. 
 
 Second mechanism is that the increased iodine directly damages thyrocytes 
by a process of oxidative stress. Increased iodine is oxidised by TPO in the 
hyperplastic thyrocytes to produce oxidative metabolites of iodine. These 
compounds are reactive and bind with proteins, nucleic acids and membrane lipids 
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and iodo compounds are produced. It causes destruction of thyroid cell and 
mitochondrial membrane integrity. Thyroid cell necrosis occurs by the production 
of free radicals. During this process autoantigen is released. Thyrocyte apoptosis 
is caused by excessive iodine intake and development of thyroid autoimmunity. 
 
Interpretation of Anti TPO antibody : <50IU/L-Negative  
       >50IU/L-Positive (Thomas et al) 
 
Interpretation of Anti Thyrglobulin  antibody 
  < 115 IU/mL (AyseArduc et al) 
 
 The production of autoimmunity may be predisposed by genetic factors, 
advancing age, environmental factors such as stress, infections, trauma, smoking 
andfemale sex due to hormonal inﬂuences. De Benoistet al demonstrated that 
Iodine plays a key role in the manifestation of autoimmune thyroiditis [94]. 
 
2.10 LIPID PROFILE IN SUBCLINICAL HYPOTHYROIDISM 
 Flower and swale et al explained that in middle of 20th century thyroid 
hormone assessment was not as easy as lipid measurement. Estimation of lipid 
profile, especially serum cholesterol level, was used as an indicator of thyroid 
hormone deficiency. Lithell et al said that Low density lipoprotein levels were 
elevated in subclinical hypothyroidism. Hypothyroidism causes lipid peroxidation 
and free radical formation leads to tissue damage [3]. 
  
 
 
 
40 
 
 
 Autoimmune thyroidits causes decreased transcription, expression and 
function of LDL receptor, impaired cholesterol degradation due to inhibition of 
cholesterol 27 –hydroxylase anti-cholesterol antibody [95]. 
 
 Efstathiadou et al proposed that apolipoprotein b and lipoprotein levels 
were increased in subclinical hypothyroid patients but no change occurs in 
triglycerides (TGL) and high density lipoprotein (HDL), but significant increase 
in total cholesterol and low density lipoprotein is noted [3]. 
 
 One analysis revealed that in subclinical hypothyroidism patients, 
Levothyroxine therapy reduces total cholesterol and low-density lipoprotein 
cholesterol (LDLc). 
 
 Caron et al reported that increase in ApoA and HDLc levels after 
Levothyroxine therapy. TOTAL CHOLESTEROL/HDLc ratio became normal. 
 
 There are reductions in LDLc, ApoB and the TOTAL CHOLESTEROL 
/HDL ratio after levothyrxine therapy in Subclinical hypothyroid patients with 
TSH level > 16.6 mIU/litre. 
 
 Levothyroxine therapy leads to reduced LDL cholesterol levels and 
improve the symptoms of subclinical hypothyroidism if TSH >12 mIU/litre. 
 
 Meier et al study reported that improvement in TOTAL CHOLESTEROL 
and LDLc levels in subclinical hypothyroid patients if TSH levels >6 mIU/litre.  
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 Law MR et al study proposed that LDLc levels decreased in subclinical 
hypothyroidism treated by levothyroxine therapy. It is useful to reduce the risk for 
coronary heart disease. 
 
 Manninen et al Helsinki Heart Study reported that 7% reduction in LDLc 
levels leads to 15% reduction in the incidence of coronary heart disease [96].  
 
 The prevalence of subclinical hypothyroidism in dyslipidemic population 
was 1.4-11.2%.   
 
 Miura et al study demonstrated that subclinical hypothyroidism patients 
showed an increase in either total cholesterol (TC) and/or low-density lipoprotein 
(LDL) cholesterol. 
 
 Kung AW, Althaus BU, Lam KS et al studies have showed that subclinical 
hypothyroidism patients had decreased levels of HDL. 
 
 Two of the 6 randomized studies support a favourable effect of thyroxine 
replacement. Caraccio et al reported that in patients with subclinical 
hypothyroidism, total cholesterol (208.8 ± 23.2 vs. 181.7 ± 23.2 mg/dL; p < 0.01), 
LDL (131.5 ± 38.7 vs. 112.1 ± 19.3 mg/dL; p = 0.01) and apolipoprotein B (107.4 
± 26.1 vs. 88.0 ± 19.7 mg/dL; p = 0.001) levels were increased. But other lipid 
parameters did not reveal any difference. Levothyroxine therapy for 6 months 
gave good results. No changes in other lipid parameters were seen. Elevated TSH 
value patients had increased reduction in total cholesterol and low density 
lipoprotein [97]. 
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 Biondi et al studies revealed that subclinical hypothyroidism should be 
treated if TSH value is <10mIU/L, because it is associated with lipid 
abnormalities. 
 
 Changes in cholesterol synthesis, metabolism, and mobilization of lipids 
may cause increase in total cholesterol and low-density lipoprotein cholesterol 
(LDL-C) [95]. 
 
FIG.9 EFFECT OF THYROID HORMONE ON CHOLESTEROL 
METABOLISM 
 
 
 HL  -  Hepatic lipase  
 LCAT  -  Lecithin –cholesterol acyltransferase 
 HDL-C  - High density lipoprotein cholesterol 
 LDL   - Low density lipoprotein 
 Hepatic HMG - Hydroxy methyl glutaryl coenzyme 
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 The hepatic expression of hydroxyl methyl glutaryl coenzyme A reductase 
stimulated by thyroid hormone leads to increased cholesterol synthesis. Hepatic 
cholesterol synthesis is decreased in overt hypothyroidism. Expression of cell 
surface LDL-C receptors expressed in fibroblasts, liver, and other tissues is 
increased by thyroid hormone. Presence of high intracellular cholesterol levels 
regulates the LDL-C receptor levels by negative feedback mechanism. This action 
is due to the presence of sterol regulatory element-binding protein-2 (SREBP-2). 
 
 T3 regulates the SREBP-2 gene. The decrease in LDL-C receptors leads to 
reduced Clearance of LDL-C from the serum. 
 
 Hypothyroidism causes an increase in the intestinal cholesterol absorption, 
because thyroid hormone acts on Niemann-Pick C1-like 1 protein in the gut.     
 
 Cholesterol from high-density lipoprotein to LDL-C and very low density 
lipoprotein is transferred by Cholesteryl ester transfer protein (CETP). 
 
 In hypothyroidism, Plasma CETP concentrations are decreased which 
produce changes in HDL-C. Hepatic lipase is regulated by thyroid hormone.  
 
 Lipoprotein lipase reduces triglyceride levels through hydrolysis of 
triglyceride-enriched lipoproteins. It causes transfer of cholesterol from these 
lipoproteins to HDL-C. Thyroid hormone increases Lipoprotein lipase activity. 
 
 In overt hypothyroid condition, serum triglycerides are elevated because of 
their lower lipoprotein lipase activity. Cholesterol is converted to bile acids and 
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excreted in faeces. Fecal excretion is an important mechanism for the removal of 
cholesterol from the body. 
 
 Kanaya AM et al study shows that an average of 9 mg/dl elevation of total 
cholesterol occurs if Serum TSH values exceeds 5.5 mIU/litre.   
 
 Canaris et al demonstrated that in Subclinical hypothyroid patients, fasting 
total cholesterol, triglyceride and LDL-C levels were increased. 
 
 Bell RJ et al study among a community-based sample survey in Australian 
women, total cholesterol, LDL-C, triglycerides, and HDL-C were equal between 
subclinical hypothyroid and euthyroid women. 
 
 Lai Y et al chinese adults survey showed that higher triglycerides and 
lower HDL-C were seen in subclinical hypothyroidism. 
 
 Monzani et al told that concentrations of apolipoproteinB (ApoB),which 
was present in LDL-C and VLDL, were increased  in subclinical hypothyroidism  
 
 Perez et al, Ito M et al study revealed thatL-T4 treatment gave good results. 
 
 Weintraub et al proposed that T4 causes an increase in the clearance of 
chylomicron remnants from serum. 
 
 Ito m et al demonstrated that Hypothyroidism is associated with elevated 
serum concentrations of remnant lipoproteins. Post prandial lipidemia is elevated 
(defined as an increase of 80% or more in serum triglycerides 4–6 h after eating) 
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in both overt and subclinical hypothyroidism. L-T4 treatment gives positive 
results[99]. 
 
 Duntas et al reported that oxidized LDL-C levels were increased in patients 
with subclinical hypothyroidism than in euthyroid. Oxidative LDL-C is 
responsible for initiation of atherosclerosis. In overt and subclinical 
hypothyroidism, size of lipid sub particle is altered [98]. 
 
 Increased lipid concentration and diastolic pressure are seen in young 
women with Subclinical hypothyroidism. It is associated with hypertension, hyper 
triglyceridaemia and elevated TGL/HDL ratio which may increase the risk of 
accelerated atherosclerosis [99]. 
 
 Triglycerides levels are elevated and HDL-C levels are decreased in 
subclinical hypothyroidism [100]. 
 
 Fremantle Diabetes study showed that in the presence of insulin resistance, 
association between TSH and lipid profile is increased. 
 
 Hyperlipidemia and subclinical hypothyroidism are present in community. 
Ineck et al reveals that prevalence of subclinical hypothyroidism in dyslipidemia 
patients ranges from 4to11.2% 
 
 Ladenson et al reported thatthyroid function test should be done in adults 
more than 35 yrs of age. 
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 For patients with subclinical hypothyroidism and hyperlipidemia, Life style 
changes are recommended and lipid-lowering drugs should be given irrespective 
of thyroxine therapy. Smoking and insulin resistance add to the effects of 
subclinical hypothyroidism on serum lipid values [99]. 
 
 Hypercholesterol levels in subclinical hypothyroidism is treated with 
thyroxine therapy for restoration of euthyroidism, for improvement of lipid levels 
and to prevent progression to overt hypothyroidism[101] 
 
TABLE NO.3 Normal values of Lipid Profile [102] 
LDL   
<70 mg/dL Therapeutic option for very high risk patients 
<100 mg/dL Optimal 
100–129 mg/dL Near optimal/above optimal 
130–159 mg/dL Borderline high 
160–189 mg/dL  High 
190 mg/dL Very high 
TOTAL CHOLESTEROL 
<200 mg/dL Desirable 
200–239 mg/dL Borderline high 
240 mg/dL High 
HDL CHOLESTEROL 
<40 mg/dL Low 
60 mg/dL High 
 
2.11 BRAINSTEM EVOKED RESPONSE AUDIOMETRY 
 Hypothyroidism is associated with hearing impairment. Kemp first 
explained this defect in severe hypothyroid patients (myxedema). Hearing loss in 
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acquired hypothyroidism was explained by Hilger. Some authors have explained 
that there is prolongation of both central and peripheral conduction time in 
hypothyroidism patients.  There is a presence of conductive, sensorineural and 
mixed hearing loss. 
 
2.11.1 Structure of inner ear 
 Inner ear is made up bony labyrinth which is located in the petrous part 
temporal bone and it contains perilymph. Membraneous labyrinth is located inside 
the bony labyrinth and it contains endolymph. 
 
It has three components  
Cochlea-It contains hair cells, the receptors for hearing. 
Semi circuar canal- It contains hair cells. It responds to head rotation  
Otolith organ-It contains hair cells. It responds to changes in gravity and head tilt.  
Basilar and Reissner’s membrane divide the cochlea into three chambers. Upper 
chamber is ScalaVestibuli and lower chamber is Scala Tympani. Both of them 
contain Perilymph. Both of them communicate with each other at the apex of 
cochlea through small opening which is known as helicotrema. Middle chamber is 
Scala Media, which contains Endolymph. The   Organ of Corti extends from the 
base to the apex of the Cochlea which contains the hair cells. 
 These hair cells act as the sensory receptors of auditory system. They are 
also known as mechanoreceptors which are responsible for hearing. It is a type of 
Mechanotransduction. They detect movement in the environment and convert 
them into electrical potentials. 
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 Two types of hair cells are arranged in four rows. Outer hair cells are 
arranged in three rows and inner hair cells are arranged in single row. Cochlea 
contains 20,000 outer hair cells and 3500 inner hair cells. The tips of outer hair 
cells   embedded in tectorial membrane. Sensory neurons to the hair cells arborise 
at their bases and their cell bodies are located in the spiral ganglion.  The efferents 
from the hair cells are forming the cochlear division of the vestibulocochlear 
nerve.  
 
 The tight junctions between the hair cells prevent the endolymph reaching 
their base of cells.  Basilar membrane is permeable to perilymph and bases of hair 
cells are bathed in peilymph. So the hair cell processes project into the endolymph 
formed by the striavascularis of the scala media .It contains high concentration of 
potassium ions. 
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2.11.2 Structure of Hair cell 
 
Fig.10. Cross-section of the cochlea and Structure of the organ of Corti 
 
 About 30-150 rod shaped hairs project from the apical surface of each hair 
cell into the fluid of cochlear duct called as stereocilia. It contains actin coated 
with myosin. 
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 Their heights are increased in a progressive manner. Tiplinks connect tip of 
this Stereocilium to the adjacent higher stereocilia. Cation channels are present at 
this junction in the taller Stereocilia.   
 
2.11.3 Function of the hair cells  
 The inner hair cells act as sensory receptors of hearing .Sound vibration 
stimulate the inner hair cells which causes the movement of fluid in inner ear. 
Action potentials are produced in inner hair cells and transmitted to the auditory 
nerve followed to brainstem. Outer hair cells are responsible for sound 
amplification and sound clarity. Outer hair cells contain prestin, which is a 
membrane motor protein and is responsible for changes in outer hair cells. 
 
2.11.4 Mechanism of action  
 The deflection of the shorter stereocilium towards the larger ones opens 
voltage gated cation channels. It is responsible for an influx of Potassium and 
Calcium ions followed by depolarisation of the cell.  The resting membrane 
potential of the hair cell is -60 mV. It decreases to -50 mV during depolarisation.  
It produces endocochlear potential. It opens more number of calcium channels and 
release of Glutamate. This neurotransmitter also stimulates the adjacent neurons 
and triggers the action potentials in the auditory nerve. 
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Fig.11 Receptor potential in hair cell 
 
 When stereocilium moves in opposite direction it produces 
hyperpolarization . 
 
2.11.5 Clinical significance 
 Hearing sensitivity is reduced if hair cells are damaged. Hair cells cannot 
regenerate and produces permanent hearing loss resulting in defective action 
potential production and delayed transmission to higher centre [10]. 
 
Evoked potentials  
 “The electrical potentials  generated  from the nervous system of  animal or 
human beings on application of a stimulus  are called as Evoked potentials”.  
 
 
 
52 
 
 
 Brainstem evoked action potentials are recorded from the ear and vertex in 
response to auditory stimulation. It gives information regarding the auditory 
pathway up to midbrain. It contains 5 or more waves or more waves. These waves 
are produced within 10minutes of stimulus. 
 
2.11.6 Uses 
1.  Identification of hearing impairment in uncooperative patients 
2.  To measure the hearing in Young children 
3.  To assess the severity of hearing deficits in infants  
4.  To know the function of the middle portion of the brainstem 
5.  To differentiate lesions of central auditory apparatus and peripheral organs   
6.  To  assess  the maturity of the central nervous system in new born   
7.  To know the  prognosis in comatosed patients,  
8.   Diagnosing brain death 
 
 “It is the recording of the activity initiated at the base of cochlea which  
moves towards the apex within 4ms period of time”. The parameters seen are   
 
Amplitude  - Number of firing neurons  
Latency   -  Transmission speed  
Inter peak latency  -  Time between peaks  
Inter aural latency  - Difference in wave latency between ears  
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2.11.7   Anatomical and Physiological basis of BAEPs 
 External and middle ear transmit the sound waves to the inner ear. 
Receptor organ for hearing is organ of corti which is located in cochlea. Cochlea 
is a coiled structure which rests on basilar membrane. Hair cells are receptor cells. 
Each hair cell contains 60 stereocilia, which are embedded in a gelatinous 
tectorial membrane overlying the organ of corti. The high frequency sounds affect 
the basal end of cochlea and low frequencies affect the apical end of cochlea. The 
amplitude of movement is related to the intensity of the acoustic signals. 
 
Fig12 Auditory Pathway 
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 Basilar membrane is supplied by eighth cranial nerve. Vibrated basilar 
membrane stimulates the eighth nerve. The latency of eighth nerve discharges 
following an acoustic signal will be shorter from the basal compared to apical end 
of cochlea. Eighth nerve has bipolar neuron. It is situated in spiral ganglion. 
Dendrites of the nerve go to hair cells and its axon goes to cochlear nucleus. Three 
sub nuclei are present in cochlear nuclei. 
 
1. Anterior ventral cochlear nucleus(AVCN) 
2. Posterior ventral cochlear nucleus(PVCN) 
3. Dorsal cochlear nucleus(DCN) 
 
 The fibres from AVCN pass through the ventral acoustic striae form 
trapezoid body which terminate in superior olivary nuclei and inferior colliculus. 
AVCN neurons discharge at short latency to acoustic stimuli with a pattern like 
eighth nerve. 
 
 Fibres from PVCN pass through ventral and middle acoustic striae. These 
fibres terminate in superior olivary nucleus and inferior colliculus. 
 
 Fibres from DCN go to superior olivary nucleus and contralateral inferior 
nucleus through dorsal striae. Discharges from this neuron have long latency. The 
cochlear nucleus terminates in superior olivary nucleus and contains medial and 
lateral part, which is located at the base of pons. 
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Medial superior olivary nucleus= ipsilateral + contralateral AVCN→Excitatory 
Lateral superior olivary nucleus= ipsilateral excitatory from AVCN and PVCN+ 
Inhibitory input from contralateral AVCN and PVCN 
Olivary nucleus→Inhibitory and contralateral lateral lemnnisci→Inferiorcolliculi 
↓ 
Neurons are affected in a nonlinear manner to binaural stimulation. 
 
 The inferior colliculi and lateral lemniscal nuclei converges the input from 
contralateral cochlear nucleus and superior olivary nucleus. 
 
 Inferior colliculi→ Medial geniculate body→ Auditory cortex (Superior 
temporal gyrus and upper bank of sylvian fissure including the frontal and parietal 
opercula). 
 
 The orientation of the neurons in DCN, medial superior olivary and lateral 
superior olivary nuclei results in summation of synaptic potentials to result in high 
amplitude electrical fields. The nuclei are connected by large myelinated fiber 
tracts and their synchronous discharges also generate cohesive voltage fields. 
 
Brainstem electrical activity and its correlation with BAEP 
 In first 10minutes after acoustic stimulus, recordings are done from 
different levels of subcortical auditory pathways. Potential corresponding to 
continuous activation of peripheral, pontomedullar, pontine, and midbrain portion 
of audiotory pathways can be recorded. The acoustic nerve and brainstem auditory 
potentials are volume conduction to surface recording electrodes. Vertex positive 
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and vertex negative waves are formed from vertex and earlobe. These waves are 
known as BAEPs. The peak to peak amplitude of these waves picked from scalp 
are only 1/100 the amplitude of ongoing spontaneous EEG activity.  
Within 10minutes of auditory stimulus, five or more waves are recoded.  
 
TABLE NO.4 Generators of BAEPs ( Chiappa et al ,1990) 
WAVEFORM GENERATORS 
I Peripheral portion of VIII cranial nerve adjacent to cochlea 
II Cochlear nucleus 
III Suprior olivary nucleus 
IV Lateral lemiscus 
V Inferior colliculi 
 
Alternate source of waves 
(Moller et al., 1988) II-Originate from the intracranial but extra medullary  
    portion of VIII nerve 
(Richter et al.,1983) III- medial nucleus of trapezoid body  
(Picton et al.,1981)   IV- originate from Lateral lemiscus but independent of  
    Inferior colliculi 
    V- Originate from high pons or low midbrain 
 
 Brain structure responsible for production of waves from III-V is closely 
packed brainstem structure. Only 2.5-4cm distance is present between entry point 
of VIII nerve and inferior colliculi [103]. 
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METHODS  
Fig.13 ELECTRODE PLACEMENT FOR BAEP 
 
 
Fig.14 NORMAL  BAEP WAVES 
 
 
   Fig.15 NORMAL VALUES OF BAEP[103] 
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History of Brainstem evoked response audiometry 
 1967- Sohmer and Feinmesser –ABRs(Auditory brainstem response) 
recorded with surface electrodes in humans and cochlear potentials was 
done by non invasive method  
 
 1971- Jewett and Williston--- Description of the human ABR and 
interpreted the later waves as arriving from the brainstem 
 1974,-Hecox and Galambos --- ABR could be used for threshold 
estimation in adults and infants.  
 In 1975- Starr and Achor---first to report the effects on the ABR of CNS 
pathology in the brainstem 
 1977-Selters and Brackman--- published landmark findings on prolonged 
inter-peak latencies in tumour cases (greater than 1 cm) [104]. 
 
2.11.8 PATHOPHYSIOLGY OF HEARING IMPAIRNMENT 
A.Uziel et al explained that deficiency of thyroid hormone causes defects 
in morphological and neuronal development of organ of corti. 
 
 Hearing impairments in acquired hypothyroidism are due to deterioration 
of oxygenation and metabolism in the organ of corti and stria vascularis. It also 
produces changes in protein synthesis, enzymes action and myelin production. 
Some conditions like Hypertension, Hyperlipidemia and electrolyte imbalance 
lead to hearing impairment. It was reported by K.T. sanos et al. 
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 J.R. Berrocal et al proposed that autoimmue mechanism is responsible for 
sensoneural hearing loss in Hashimotos’s thyroiditis. Possible mechanism is 
mainly vascular. It is also due to neuronal degenaration, endolymphatic edema 
and fibrous tissue proliferation, compression of perilymphatic sac and atrophy of 
the organ of corti due to the vascular and inflammatory processes of autoimmune 
damage.   
 
 Gawron et al evaluated hearing function in children with Hashimotos’s 
thyroiditis showed that hearing disturbances in auditory nerve and brainstem 
neural conduction in brain auditory evoked potential. He found that positive 
correlation is between anti-TPO levels and extent of hearing defects in 
Hashimotos’s thyroiditis. 
 
There is also a positive association with anti-Tg levels [105]. 
 Hypothyroidism causes atherosclerosis which leads to peripheral vascular 
disease, deafness and coronary artery disease [1]. 
 Figueiredo et al found that subclinical hypothyroid patients showed marked 
difference in the absolute latencies of waves III and V and interpeaks LI-III, LIII-
V, and LI-V [106]. 
 Cristiane et al found out that inter peak latency was increased in subclinical 
group [107] 
 
2.12 Dyslipedemia and hearing loss  
 “Cochlea- the lipid composition, fluidity, and stiffness of the outer hair cell 
lateral wall membrane have been shown to be important to its electromotile 
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function and the cochlear amplifier”. The lateral wall plasma membrane of the 
outer hair cell has less cholesterol than other cells. 
 Hypercholesterolemia reduces cochlear vascularity leads to hearing loss. 
M. Bradley Evans et al explained that chronic dyslipidemia and elevated 
triglycerides decrease the auditory function. 
 Rosen et al demonstrated that reduced hearing occurs in dyslipidemia. But 
other studies do not show any significant relation between cholesterol and hearing 
loss [108]. 
 
2.13 Thyroid antibodies and hearing loss 
 Gawron et al. reported that subclinical Hashimoto encephalopathy 
produced changes in central part of auditory organ. Positive correlation exists 
between the anti-TPO levels and the changes in the central part of the hearing 
organ [109]. İlhan documented that abnormal BERA findings were due to 
autoimmunity which was shown by presence of correlation between elevated anti-
Tg and anti-TPO and BERA parameter [110]. Leventrenda documented that 
antibodies directed against spiral ligament, striavasculris and supporting cells[111]. 
 Naemaismail reported that autoimmunity was a cause for hypothyroidism. 
Auditory system affected due to endolymphatic edema, neuronal degeneration, 
fibrous tissue proliferation, atrophy of organ corti. He found that statistically 
insignificant correlation between thyroid peroxidase antibody and changes in 
auditory brainstem response [112]. 
  
Aim and objectives 
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3. AIM AND OBJECTIVES OF THE STUDY 
 
Aim:  
 To evaluate the audiologic function in newly diagnosed subclinical 
hypothyroidism patients by BERA 
 
Objective: 
1. To assess Age, Sex, Height, Weight, BMI                                                                                     
2. To assess the levels of TSH, fT4, fT3 in newly diagnosed subclinical 
hypothyroid patients  
3. To assess levels of Thyroglobulin antibody and Thyroid peroxidase 
antibody if TSH>5.1mIU/L,fT4>0.93 to 1.7 ng/dl, fT3- >3.1 to 6.pmol/L 
4. To assess the serum lipid profile 
5. To do Brainstem evoked response audiometry to rule out changes in 
peripheral and central auditory pathway 
6. Compare all the parameters with healthy age and sex matched controls. 
7. To do correlation of Brainstem evoked response audiometry (BERA) with 
thyroid antibodies and lipid profile 
 
  
Materials and Methods 
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4. METHODOLOGY (MATERIALS & METHODS) 
 
 The study was conducted in the year between 2016-2017 in the Institute of 
Physiology and Experimental medicine, Madras Medical College. This study was 
done after getting approval from Institutional Ethics committee, Madras Medical 
College, Chennai. 
 
4.1Subject Selection: 
 Thirty newly diagnosed patients of subclinical Hypothyroidism of both 
sexes, in the age group below 60 years were included in the study. They were 
selected from the Medical Endocrine Clinic, Rajiv Gandhi Government general 
Hospital, Chennai. 
 
 Thirty control subjects of both sexes, in the age group below 60 years with 
normal thyroid profile were selected. 
 
4.2   Inclusion Criteria: 
 Patients are both men and women in the age group below 60 years with 
TSH >5.1mIU/L, fT4>0.93 to 1.7 ng/dl, fT3- >3.1 to 6.8pmol/L 
 
4.3   Exclusion Criteria: 
Patients with:   
 Neurological or psychiatric illness 
 Altered sensorium  
 Any other medical disorder that can affect hearing like diabetes 
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mellitus, anemia, hypertension, chronic obstructive pulmonary disease, 
acute or chronic liver disease, and acute or chronic renal disease 
 Malignancy  
 History of drug abuse and alcoholism 
 Above 60 years 
 Pregnancy 
 
4.4  STUDY CENTRE 
 Institute of Physiology and Experimental Medicine, Medical endocrine 
Clinic, Rajiv Gandhi Government General Hospital, Madras Medical College, 
Chennai- 3. 
 
4.5 STUDY DESIGN: Case control study 
4.6 EXAMINATIONS 
A. General examination 
B. Examination of thyroid gland 
C. Specific ENT examination   
 
 Both the control and study group individuals were subjected for basic ENT  
examination.  It includes external ear examination, tuning fork tests like rinne’s 
test and weber’s test, Otoscopic examination. 
  
 
 
 
64 
 
 
Pure tone audiometry  
 Pure tone audiometry examination was done in both control and subclinical 
hypothyroid patients. To find out; 
1. Hearing threshold of the subjects 
2. To find out external or middle ear pathology 
 
 D.Brainstem Auditory Evoked Potential   
 The patients with subclinical hypothyroidism and controls were subjected 
to the non invasive assessment of hearing by Brainstem Evoked Response 
Audiometry (BERA).  It was done by Computerised Neurostim, Medicaid system. 
 
1. Apparatus for BERA   
 “The apparatus for eliciting   brainstem evoked response audiometry are set 
as per the “Recommended standards for the clinical practice of evoked potentials”  
which is introduced in Guideline 9A: Guidelines on evoked potential, by 
American society of Clinical Neurophysiology.” 
 
Pulse generator   
 The stimulusis given in the form of in the form of clicks or tone pips. It is 
conducted in to the ear through the transducer placed in the headphone. 
 
Recording electrodes  
 Three recording electrodes are placed as per the International 10-20 
electrode placement system. 
1. Active electrode- placed on the ipsilateral mastoid process 
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2. Reference electrode- placed on the vertex and a   
3. Ground  electrode-placed in front of reference electrode 
 
There are two varieties are electrodes are used during recording processes. 
1. Needle electrodes   
2. Surface electrodes 
 
 The surface electrodes are commonly used. It does not produce pain 
sensation and infection rate also reduced. Ask the subject to take head bath before 
coming for examination for easy application of electrodes. Disc electrodes of 1cm 
size and with conducing jelly or paste are used. <5 kilo ohms of electrical 
impedance are used for good recording.             
 
Filters  
Filter is a device that restricts selectively the frequency domain of the 
signal. Frequency band pass means frequency range of a signal transmitted 
through the filter.  
 Stop band means signal rejected in that particular frequency range. 
 Transition lies between the frequency and stop band. 
 
Uses 
1. Noise elimination 
2. Optimal recording 
3. To obtain typical wave forms 
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I. Low frequency filter-It removes slowly changing low frequency and 
allows higher frequencies. It also known as high pass filter. 
II. High frequency filter- It removes rapidly changing high frequency and 
allows low frequencies. It is also known as low pass filter. 
 
Amplifier 
 500000 times of amplification is needed before displayed due to following 
reasons. 
1. Biological signals are small 
2. Intrinsic impedance of electrode. It changes with frequency and electrode 
type used. 
3. Impedance of electrode- skin 
For the measurement of any electrical activity including action potential 
which is generated in central nervous system, nerve or muscle should flow 
through the ground lead. 
 
 Electrode impedance produces a drop in the amplitude of the action 
potential. It amplifies the attenuated action potential. Action potential reaching the 
amplifiers is attenuated action potential. The impedance of the amplifiers should 
be greater than electrode impedance to reduce this attenuation.  A100:1 ratio of 
electrode to amplifier impedance is maintained across the range of frequencies in 
the waveform under study.  
1. Due to amplification waveforms distortion are minimized  
2. Improves noise rejection. 
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Signal average 
 It is difficult to measure electrical activity of brain using sound stimuli 
given to the ear. Because spontaneous electrical activity is generated within the 
brain (Back ground potential).So the electrical activity set up in the brain in 
response to sound stimulus gets masked by spontaneous electrical activity 
occurring in the brain. 
 
 It used to extract small signals. Because it is hidden by large noise like 
evoked potential buried in EEG. Evoked electrical activity is time specific which 
occurs at a fixed point of time after the sound stimulation but spontaneous 
electrical activity occurring randomly not time specific. By averaging, the time-
locked signals become prominent and stored in machine. If noise occurs which is 
cancelled or time –locked and rejected subsequently. 
 
Electrical safety; All instruments should be checked periodically. It helps to 
protect from shock during power fluctuations.   
 
2. Recordings procedure of BERA    
Fig .16Recordings for BAEP waveforms 
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 The recording was done in semi darkened and quiet room. The patient is 
advised to take head bath before recording. Electrodes placing areas are cleaned. 
Active, reference & ground electrodes are kept in a appropriate places.  Below 5 
kilo ohms levels of resistance are used. Auditory stimulus consists of clicks of 
100µsec are given in one ear .It is given through electrically shielded ear phones 
at the rate of11.1 clicks/sec.  
 
 Another ear is masked by pure white noise of 40dB.It is used to prevent 
false BAEP response. To filter out undesirable frequencies in the surroundings we 
had to use band pass of 150-3000 Hz. Responses to 2000 clicks presentations 
were averaged. 
 
 A graph is plotted to show the result. X-axis contains time (in milliseconds 
from the onset of stimulus).Y-axis contains amplitude (in µvolts).5-7wave or 
peaks are seen within 8-10 milliseconds. It is marked with Roman numerals. 
 
Waveforms were analyzed for the following characters. 
o Latency 
o Amplitude  
o Morphology  
It gives information about cochlear and retro cochlear function.   
 
Wave I 
It gives information about potentials generated in the peripheral part of 8th cranial 
nerve. It is a prominent initial peak confined to ipsilateral ear and is absent in 
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contralateral ear. It appears 1.5 ms after the application of stimulus .It is decreased 
in patients with peripheral hearing impairment   
Wave II  
       It is appears as small peak.It appears 2.8ms after application of stimulus. It is 
absent in lesions of the cochlear nucleus.   
Wave III 
      Itis a prominent peak followed by a prominent trough. It appears 3.9 ms after 
the click stimulus. It is absent in superior olivary nucleus lesion. 
Wave IV 
    It appears as peak in the up going slope of after 5.1ms. Wave IV is absent in 
lateral lemniscus lesion   
Wave V 
Itis the most prominent peak. It appears 5.5 msec after the stimulus.It is absent 
inferior colliculi lesions. This wave component is analysed most often in clinical 
applications  
Wave VI and VII 
 These waves are origin from subcortical structures like medial geniculate body 
and auditory radiation. It appears 7.3 and 9.6 ms after initiation of stimulus. 
 
3. Wave forms interpretation 
     The parameters taken into consideration for studying the waveforms of  
BAEPs are  
Absolute latency; It is the time interval and it is measured by milliseconds. It is 
starting point of stimulus to the peak of the wave.    
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Absolute amplitude; It is measured in microvolt. It is marked as the height from 
the peak of the wave to its trough. It is measured by microvolt. Amplitude of the 
waves is not as constant as latency and not reliable.   
 
Inter peak latency (IPL):  The duration between two different waves in the same 
ear is known as inter peak latency. It is also known as inter peak latency or inter 
wave latency. There are three inter peak latency most commonly used. 
1. I-V----latency difference between wave V and I. It denotes the conduction 
from proximal VIII nerve through pons to midbrain. Normal duration is 
4msec. It is shorter in young women and in older men becomes longer. It is 
prolonged in demyelination, ischemia, tumours, brain damage due to 
hypoxia. 
2. I-III- it is a latency difference between wave I and III .It denotes 
conduction from VIII nerve across subarachnoid space. Normal is 
2.1msec.It is prolonged in tumour or inflammation affecting the proximal 
portion of the VIII nerve. 
3. III-V—It denotes conduction from lower pons to midbrain .Normal 
duration is 1.9msc 
 
Amplitude ratio of wave V/I: Wave I is generated outside and wave v is 
generated inside the central nervous system. This is used to compare the 
relationship of the expected signal amplitude.  Normal ratio is 50 %and 300%  
 If ratio exceeds 300%,it shows peripheral hearing impairment. If ratio is lower 
than 50%, it denotes central hearing loss.   
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Inter aural latency difference: It should be less than 0.5msec.It is the time 
interval between the two ears for same wave during supra threshold stimulus[113] 
 
4. Technical factors  
Stimulus rate: Number of clicks is given. It is 10-70times/seconds 
Intensity of the sound stimulus; High intensity- wave I is decreased with 
prolonged I-V IPL. With decreasing intensity-I, III, V waves are present. Still 
lower intensity (10dBSL) V wave is seen. 
Stimulus phase or polarity:  The pulse can move towards or away from the ear. 
The ear phone movement toward the ear is called condensation phase moves away 
from the ear  it is called as rarefaction phase. 
Filter; lower frequency filter -100 or 150 Hz   
            High frequency filter- 3000 Hz  
 
Nature of sound: Click stimulus was given for 1ms duration. The stimulus 
applied is usually square wave pulse. The sound stimuli delivered at 50-60 db 
above the hearing threshold.    
 
Binaural/monaural stimulation: In clinical studies, monaural stimulation is 
recommended. If both ears are stimulated the amplitude of the waves III, IV, V 
are increased[114]. 
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5.Nontechnical factors 
Age; Older adults have longer I-V IPL by 0.1-0.15ms 
Temperature: The absolute latency (7% for 1 celsius) and IPL are prolonged on  
lowering  body temperature. 
Hearing status; Ear canal examination and hearing should be tested. 
Drugs:  “BAEPs are resistant to the effect of drugs, but a slight prolongation of V 
wave latency with barbiturates or alcohol is attributed to the lowering of 
temperature” 
 
6. Terminologies used in evoked potential study 
Hearing level 
         It refers to the number of decibels of intensity compared to the threshold of 
hearing in a group of normal persons. Zero means threshold at which a normal 
subject can just perceive 50% of stimuli. 
 
Sensory level (dB SL) 
 Zero is defined as the point at which the individual can barely appreciate 
the stimulus. 
 
Decibel (dB=1/10 Bel) 
 It is defined as ’20 log (P1/P2)’, where P1 is the intensity of the sound to be 
measured andP2 is the intensity of the reference sound[103].   
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4.7. SAMPLE COLLECTION 
After obtaining informed consent, under aseptic precautions, 5-10ml of  
blood would be taken for estimation of TSH ,fT4,fT3,( ElectroChemiluminescence 
immunoassay),Thyroglobulin antibody  (Anti-Tg Elecsys e 100  kit),Thyroid 
peroxidase antibody(Anti-TPO Elecsyscobas kit)  and lipid profile 
 
4.8 STATISTICAL ANALYSIS 
 
1. Using unpaired t test the mean variables between the normal and 
subclinical hypothyroid patients are compared. SPSS version 17 was used 
for data analysis. 
 
2. Pearson’s coefficient was done to find out the correlation between BERA 
with thyroglobulin antibody, thyroid peroxidase antibody and lipid profile 
in subclinical hypothyroid patients. 
  
Results 
  
 
 
 
74 
 
5.RESULTS 
 
 All the Subclinical hypothyroid patients and controls enrolled for the 
present study had clinically no evidence of hearing deficit. 
 
5.1 Characteristics of study and control subjects 
 Our study population consists of 30 subclinical hypothyroid patients in the 
age group 20-60 years without any clinical evidence hearing impairment. The 
control subjects were 30 in number belonging to the age ranging from 20-60 
years. 
 
5.2 Levels of Thyroid antibodies and lipid profile 
 The difference in the mean values of thyroid antibodies and lipid profile 
between controls and subclinical hypothyroid patients are given in table 9 and 10. 
 
5.3 Brainstem auditory evoked potential parameters 
 Variable pertaining to BERA between normal and are subclinical 
hypothyroid patients are given in the tables 11-34 and also represented in graph 
(10-20).  BERA parameters are utilized for evaluating the integrity of auditory 
pathway. 
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TABLE NO.5 Comparison of mean values of Height between controls and  
subclinical hypothyroid patients 
pvalue –not significant 
 
TABLE NO.6 Comparison of mean values of weight between controls and 
subclinical hypothyroid patients 
 GROUPING N Mean 
Std.  
Deviation 
Std.  
Error Mean t DF 
p 
Value 
WT 
(kg) 
CONTROL  
GROUP 30 59.6 9.999 1.825 
-3.867 58 0.000* 
STUDY 
GROUP 30 69.63 10.101 1.844 
pvalue – significant 
 
TABLE NO.7 Comparison of mean values of body mass index between 
controls and subclinical hypothyroid patients 
 GROUPING N Mean 
Std.  
Deviation 
Std.  
Error Mean t DF 
p 
Value 
BMI 
CONTROL  
GROUP 30 22.148122 2.7366318 0.4996383 
-5.945 58 0.000* 
STUDY  
GROUP 30 27.498865 4.1004333 0.7486333 
p  value – significant 
  
 GROUPING N Mean 
Std.  
Deviation 
Std.  
Error Mean t DF 
p 
Value 
HT 
(m) 
CONTROL  
GROUP 30 1.639 0.12067 0.02203 
1.541 58 0.129 
STUDY  
GROUP 30 1.5943 0.10321 0.01884 
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TABLE NO.8 Comparison of mean values of Free T3, Free T4 and thyroid 
stimulating hormone levels between controls and subclinical hypothyroid 
patients 
 GROUPING N Mean 
Std.  
Deviation 
Std.  
Error Mean T DF 
p 
Value 
T3  
(pmol/L) 
CONTROL 
GROUP 30 4.53 0.92295 0.16851 
0.197 58 0.844 
STUDY 
GROUP 30 4.4867 0.77417 0.14134 
T4 
(ngm/dl) 
CONTROL 
GROUP 30 1.2273 0.25308 0.04621 
2.354 43.987 0.023 
STUDY 
GROUP 30 1.1043 0.13354 0.02438 
TSH 
(µIU/ml) 
CONTROL 
GROUP 30 3.5267 0.48703 0.08892 
-10.295 29.528 0.000* 
STUDY 
GROUP 30 13.1673 5.10568 0.93217 
p  value –not significant in Free T3, Free T4 
p  value –significant in thyroid stimulating hormone 
 
 
TABLE NO.9 Comparison of mean values of thyroglobulin antibody and  
thyroid peroxidase antibody between controls and  
subclinical hypothyroid patients 
 GROUPING N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
t DF p Value 
Anti-Tg 
(IU/ml) 
CONTROL 
GROUP 30 29.334 33.43902 6.1051 -
5.453 31.863 0.000* STUDY 
GROUP 30 182.6353 150.31079 27.44287 
Anti-
TPO 
(IU/ml) 
CONTROL 
GROUP 30 55.5687 116.06911 21.19122 -
5.424 41.497 0.000* STUDY 
GROUP 30 323.0273 243.87572 44.52541 
p  value–significant in Anti-Tg, Anti-TPO 
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TABLE NO.10 Comparison of mean values of lipid profile between controls 
and subclinical hypothyroid patients 
 GROUPING N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
t DF p Value 
TOTAL 
CHOLESTEROL 
 
(mg/dl) 
CONTROL 
GROUP 30 174.7 18.234 3.329 
-2.982 38.17 0.005* 
STUDY 
GROUP 30 201.27 45.266 8.264 
HDL 
(mg/dl) 
CONTROL 
GROUP 30 52.9 7.48 1.366 
1.933 42.827 0.06 
STUDY 
GROUP 30 47.03 14.85 2.711 
TGL 
mg/dl 
CONTROL 
GROUP 30 143.67 8.193 1.496 
-0.383 29.592 0.704 
STUDY 
GROUP 30 149.37 81.099 14.807 
VLDL mg/dl 
CONTROL 
GROUP 30 28.733333 1.6386145 0.2991687 
-0.383 29.592 0.704 
STUDY 
GROUP 30 29.873333 16.2197396 2.9613058 
LDL 
mg/dl 
CONTROL 
GROUP 30 93.066667 16.9846449 3.1009577 
-3.742 38.017 0.001* 
STUDY 
GROUP 30 124.36 42.5399253 7.7666922 
LDL/ 
HDL 
CONTROL 
GROUP 30 1.795321 0.4117805 0.0751805 
-3.04 30.716 0.005* 
STUDY 
GROUP 30 3.142826 2.3926494 0.436836 
TGL/ 
HDL 
CONTROL 
GROUP 30 2.771594 0.4437766 0.0810222 
-1.869 30.606 0.071 
STUDY 
GROUP 30 3.693572 2.6659285 0.4867297 
 
p  value –significant in total cholesterol LDL and LDL/HDL 
 
 
 
 
Graph 1.Comparison of mean values of BMI between controls  
and subclinical hypothyroid patients 
 
 
 
 
Graph.2 Comparison of mean values of T4between controls and subclinical 
hypothyroid patients 
 
 
  
22.1
27.4
0
5
10
15
20
25
30
CONTROL GROUP STUDY GROUP
BMI
CONTROL GROUP
STUDY GROUP
1.2273
1.1043
1
1.05
1.1
1.15
1.2
1.25
CONTROL GROUP STUDY GROUP
T4 (ngm/dl)
CONTROL GROUP
STUDY GROUP
 
 
 
 
Graph. 3 Comparison of mean values of T3between controls and subclinical 
hypothyroid patients 
 
 
 
 
Graph.4 Comparison of mean values of TSH between controls and subclinical 
hypothyroid patients 
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Graph .5Comparison of mean values of Anti-TPO between controls and 
subclinical hypothyroid patients 
 
 
 
 
Graph.6 Comparison of mean values of Anti-Tgbetween controls and subclinical 
hypothyroid patients 
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Graph. 7Comparison of mean values of Total Cholesterol between controls and 
subclinical hypothyroid patients 
 
 
 
 
Graph .8Comparison of mean values of LDL between controls and subclinical 
hypothyroid patients 
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Graph .9Comparison of mean values of TGL/HDL between controls and 
subclinical hypothyroid patients 
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TABLE NO.11 Comparison of the mean values of absolute latencies of wave I 
between controls and subclinical hypothyroid patients in the right ear. 
 
 GROUPING N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
t DF p Value 
Right 
Ear 
wave I 
CONTROL 
GROUP 30 1.691 .11 .02008 
.0408 58 .968 
STUDY 
GROUP 30 1.69 .077 .01406 
p  value-not significant 
 
 
TABLE NO.12 Comparison of mean values of absolute latencies of wave I 
between controls and subclinical hypothyroid patients in the left ear 
 
 GROUPING N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
T DF p Value 
Left 
ear 
Wave 
I 
CONTROL 
GROUP 30 1.6517 .17360 .03170 
-.396 58 .693 
STUDY 
GROUP 30 1.6713 .20921 .03820 
p  value-not significant 
 
 
TABLE NO.13 Comparison of mean values of absolute latencies of wave II 
between controls and subclinical hypothyroid patients in the right ear 
 
 GROUPING N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
t DF p Value 
Right 
Ear 
Wave 
II 
CONTROL 
GROUP 30 2.7530 .06929 .01265 
-.270 58 .788 
STUDY 
GROUP 30 2.7573 .05413 .00988 
p  value-not significant 
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TABLE NO.14 Comparison of mean values of absolute latencies of wave II 
between controls and subclinical hypothyroid patients in the left ear 
 
 GROUPING N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
t DF p Value 
Left 
ear 
Wave 
II 
CONTROL 
GROUP 30 2.7137 .17431 .03182 
-.886 58 .379 
STUDY 
GROUP 30 2.7553 .18957 .03461 
p  value-not significant 
 
 
TABLE NO.15 Comparison of mean values of absolute latencies of wave III 
between controls and subclinical hypothyroid patients in the right ear 
 
 GROUPING N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
t DF p Value 
 
Right 
ear 
Wave 
III 
 
 
CONTROL 
GROUP 30 3.6687 .14638 .02672 
-.739 58 .463 
STUDY 
GROUP 30 3.6987 .16735 .03055 
p  value-not significant 
 
 
TABLE NO.16 Comparison of mean values of absolute latencies of wave III 
between controls and subclinical hypothyroid patients in the left ear 
 
 GROUPING N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
t DF p Value 
Left 
ear 
Wave 
III 
CONTROL 
GROUP 30 3.7117 .19785 .03612 
-.629 58 .532 
STUDY 
GROUP 30 3.7460 .22391 .04088 
p  value-not significant 
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TABLE NO.17 Comparison of mean values of absolute latencies of wave IV 
between controls and subclinical hypothyroid patients in the right ear 
 
 GROUPING N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
t DF p Value 
Right 
Ear 
Wave 
IV 
CONTROL 
GROUP 30 4.8320 .08961 .01636 
-.235 58 .815 
STUDY 
GROUP 30 4.8370 .07484 .01366 
p  value-not significant 
 
 
TABLE NO.18 Comparison of mean values of absolute latencies of wave IV 
between controls and subclinical hypothyroid patients in the left ear 
 
 GROUPING N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
t DF p Value 
Left 
ear 
Wave 
IV 
CONTROL 
GROUP 30 4.7420 .20965 .03828 
-.804 58 .425 
STUDY 
GROUP 30 4.7880 .23301 .04254 
p  value-not significant 
 
 
TABLE NO.19 Comparison of mean values of absolute latencies of wave V 
between controls and subclinical hypothyroid patients in the right ear 
 
 GROUPING N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
t DF p Value 
Right 
Ear 
Wave 
V 
CONTROL 
GROUP 30 5.6727 .16328 .02981 
-2.116 45.494 0.040* 
STUDY 
GROUP 30 5.8020 .29228 .05336 
p  value-significant 
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TABLE NO.20 Comparison of mean values of absolute latencies of wave V 
between controls and subclinical hypothyroid patients in the left ear 
 
 GROUPING N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
t DF p Value 
Left 
ear 
Wave 
V 
CONTROL 
GROUP 30 5.6250 .12913 .02358 
-2.804 39.792 0.008* 
STUDY 
GROUP 30 5.7893 .29393 .05366 
p  value- significant 
 
 
TABLE NO.21 Comparison of mean values of I-III IPL between controls and 
subclinical hypothyroid patients in the right ear. 
 
 GROUPING N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
T DF p Value 
Right 
Ear 
IPL 
I-III 
CONTROL 
GROUP 30 1.9780 .17065 .03116 
-.706 58 .483 
STUDY 
GROUP 30 2.0090 .16961 .03097 
p  value-not significant 
 
 
TABLE NO. 22 Comparison of mean values of I-III IPL between controls 
and subclinical hypothyroid patients in the left ear 
 
 GROUPING N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
t DF p Value 
Left 
ear 
IPL 
I-III 
CONTROL 
GROUP 30 2.0600 .22364 .04083 
-.242 58 .810 
STUDY 
GROUP 30 2.0747 .24611 .04493 
p  value-not significant 
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TABLE NO.23 Comparison of mean values of III-V IPL between controls 
and subclinical hypothyroid patients in the right ear 
 
 GROUPING N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
t DF p Value 
Right 
Ear 
IPL 
III-V 
CONTROL 
GROUP 30 2.0040 .18906 .03452 
-1.446 46.590 .155 
STUDY 
GROUP 30 2.1033 .32523 .05938 
p  value-not significant 
 
 
TABLE NO.24 Comparison of mean values of III-V IPL between controls 
and subclinical hypothyroid patients in the left ear 
 
 GROUPING N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
t DF p Value 
Left 
ear 
IPL 
III-
V 
CONTROL 
GROUP 30 1.9133 .26084 .04762 
-1.651 58 .104 
STUDY 
GROUP 30 2.0433 .34336 .06269 
p  value-not significant 
 
 
TABLE NO.25 Comparison of mean values of I-V IPL between controls and 
subclinical hypothyroid patients in the right ear 
 
 GROUPING N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
T DF p Value 
Right 
Ear 
IPL I-
V 
CONTROL 
GROUP 30 3.9820 .21661 .03955 
-1.985 58 .052 
STUDY 
GROUP 30 4.1123 .28712 .05242 
p  value-not significant 
  
 
 
 
 
Graph.10 Comparison of mean values of absolute latencies of wave II 
between controls and subclinical hypothyroid patients in the right ear 
 
 
 
 
Graph.11 Comparison of mean values of absolute latencies of wave V 
between controls and subclinical hypothyroid patients in the right ear 
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Graph.12Comparison of mean values I-III IPL between controls and 
subclinical hypothyroid patients in the right ear. 
 
 
 
Graph.13Comparison of mean values of absolute latencies of wave III 
between controls and subclinical hypothyroid patients in the left ear 
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Graph.14Comparison of mean values I-III IPL between controls and 
subclinical hypothyroid patients in the left ear. 
 
 
 
 
Graph.15Comparison of mean values III-V IPL between controls and 
subclinical hypothyroid patients in the left ear. 
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Graph.16Comparison of the mean values of I-V IPL between controls and 
subclinical hypothyroid patients in the left ear. 
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TABLE NO.26 Comparison of mean values of I-V IPL between controls and 
subclinical hypothyroid patients in the left ear 
 
 GROUPING N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
t DF p Value 
Left 
ear 
IPL 
I-V 
CONTROL 
GROUP 30 3.9733 .24055 .04392 
-1.915 58 .060 
STUDY 
GROUP 30 4.1180 .33673 .06148 
p  value-not significant 
 
 
TABLE no.27 Correlation between Anti-Tg and Right Ear BERA Wave V in 
subclinical hypothyroid patients 
 
Right Ear Wave V Vs. Anti-Tg (IU/ml) 
 Mean Std. Deviation N 
Right Ear Wave V 5.8020 .29228 30 
Anti-Tg (IU/ml) 182.6353 150.31079 30 
Pearson Correlation 0.32172 p VALUE 0.083 
*p Value Significant at the level <0.05 
Positive correlation, p value is not significant 
 
 
TABLE NO.28 Correlation between Anti-Tg and left Ear BERA Wave V 
in subclinical hypothyroid patients. 
Left Ear Wave V Vs. Anti-Tg (IU/ml) 
 Mean Std. Deviation N Left ear Wave V 5.7893 .29393 30 
Anti-Tg (IU/ml) 182.6353 150.31079 30 
Pearson Correlation 0.216093 p VALUE 0.251425 
*p Value Significant at the level <0.05 
 
Positive correlation, p value is not significant 
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TABLE NO.29 Correlation between the Anti-TPO and Right Ear BERA 
Wave V in subclinical hypothyroid patients. 
 
Right Ear Wave V Vs. Anti-TPO (IU/ml) 
 Mean Std. Deviation N 
Right Ear Wave V 5.8020 .29228 30 
Anti-TPO (IU/ml) 323.0273 243.87572 30 
Pearson Correlation 0.286752 p VALUE 0.1245 
*p Value Significant at the level <0.05 
Positive correlation, p value is not significant 
 
 
TABLE NO.30 Correlation between Anti-TPO (IU/ml) and left Ear BERA 
Wave V in subclinical hypothyroid patients. 
 
Left ear Wave V Vs. Anti--TPO (IU/ml) 
 
 Mean Std. Deviation N 
Left ear Wave V 5.7893 .29393 30 
Anti-TPO (IU/ml) 323.0273 243.87572 30 
Pearson Correlation 0.126845 p VALUE 0.5042 
*p Value Significant at the level <0.05 
Positive correlation,p value is not significant 
 
 
TABLE NO.31 Correlation between Total Cholesterol and Right Ear BERA 
Wave V in subclinical hypothyroid patients. 
 
Right Ear Wave V Vs. Total cholesterol (mg/dl) 
 
 Mean Std. Deviation N 
Right Ear Wave V 5.8020 .29228 30 
Total cholesterol(mg/dl) 201.27 45.266 30 
Pearson Correlation -0.16 p VALUE 0.400 
*p Value Significant at the level <0.05 
 
Negative correlation, p value is not significant 
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TABLE NO.32 Correlation between Total cholesterol and left Ear BERA 
Wave V in subclinical hypothyroid patients 
 
Left ear Wave V Vs. Total Cholesterol (mg/dl) 
 Mean Std. Deviation N 
Left ear Wave V 5.7893 .29393 30 
Total Cholesterol(mg/dl) 201.27 45.266 30 
Pearson 
Correlation -0.237 p VALUE 0.208 
*p Value Significant at the level <0.05 
Negative correlation, p value is not significant 
 
 
TABLE NO.33 Correlation between LDL and Right Ear BERA Wave V in 
subclinical hypothyroid patients 
 
Left ear Wave V Vs. LDL mg/dl 
 Mean Std. Deviation N 
Right Ear Wave V 5.8020 .29228 30 
LDL mg/dl 124.360000 42.5399253 30 
Pearson Correlation -0.256 p VALUE 0.172 
*p Value Significant at the level <0.05 
Negative correlation, p value is not significant 
 
 
TABLE NO.34 Correlation between LDL and left Ear BERA Wave V in 
subclinical hypothyroid patients 
 
Left ear Wave V Vs. LDL mg/dl 
 Mean Std. Deviation N 
Left ear Wave V 5.7893 .29393 30 
LDL mg/dl 124.360000 42.5399253 30 
Pearson Correlation -0.328 p VALUE 0.077 
*p Value Significant at the level <0.05 
Negative correlation, p value is not significant 
 
 
 
GRAPH.17 Correlation between Total Cholesterol and Right Ear BERA 
Wave V in subclinical hypothyroid patients. 
 
 
GRAPH.18 Correlation between Total Cholesterol and left Ear BERA Wave 
V in subclinical hypothyroid patient 
 
 
 
 
 
GRAPH.19 Correlation between LDL and Right Ear BERA Wave V in 
subclinical hypothyroid patients 
 
 
 
 
GRAPH. 20 Correlation between LDL and left Ear BERA Wave V in 
subclinical hypothyroid patients 
 
 
Discussion 
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6. DISCUSSION 
 Central nervous system dysfunction and hearing loss are seen in subclinical 
hypothyroidism patients. Sensorineural deafness is the most common 
manifestation due to dysfunction of thyroid gland. Few studies reveal that 
brainstem evoked response audiometry shows changes in subclinical 
hypothyroidism. 
 
 Thomas cyriac reported that prevalence of subclinical hypothyroidism and 
hypothyroidism is 15% and 11.7% respectively [94]. 
 
 Danese et al suggested that periodic examination of TSH should be done 
after 35 years of age [115]. 
 
 About 30 newly diagnosed hypothyroid patients and 30 controls are 
included in my study in the age group of below 60 years. 
 
 Characteristic of parameters between cases and controls 
 
6.1 Age 
 My present study shows that there is no specific difference in age group 
between subclinical hypothyroidism patients and controls. My study has similar 
findings with kirti Sharma study but Samuels et al reported that hypothyroidism 
is most common in elderly women, particularly in the presence of thyroid 
autoantibodies[107, 116]. 
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 Unnikrishnan AG and VanderpumpMP. T reported that increased 
prevalence of hypothyroidism is seen in age group of 46-54 years (13.1%) [117]. 
 
6.2 Gender 
 Most of the patients in my study are females. My study is supported by 
Sangeeta Gupta et al, UnnikrishnanAG  andVanderpump MP. T. They 
reported that Subclinical hypothyroidism is more common in females [118,117]. 
 
6.3 Height  
 On comparing the height between subclinical hypothyroidism patients and 
controls, it is observed that there exists (p value=0.129) no significant difference 
between the both groups.Kirti Sharma study has the same finding like my study 
[107]. p Value is statistically not significant. 
 
6.4 Weight                                                                                                          
 On comparing the weight between subclinical hypothyroidism patients and 
controls, it shows that weight gain (p= 0.000)is present in subclinical hypothyroid 
patients. p Value is statistically significant.            
 
 My findings are supported by Mario Rotondi, he reported that lipid 
deposition occurs along with increase in TSH levels.  Free thyroid hormone 
controls TSH secretion from pituitary by negative feedback mechanism. This 
feedback mechanism fails in obesity [119]. 
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6.5 Body mass index (BMI) 
 On analysing the present data, it is obvious that subclinical hypothyroid 
patients have significant increase in body mass index (p value=0.000). p Value is 
statistically significant. 
 
 Gauravgupta study reported that increased weight gain is seen in 
subclinical hypothyroid patients and changes in basal metabolic rate and 
environmental factors leads to obesity by unknown biological mechanism [120]. 
 
 Milionis A, Milionis C reported that environmental factors contribute to 
weight gain in Subclinical hypothyroid patients [121].  
 
Controversy to my study was explained by Kirti Sharma, he reported that 
no difference in body mass index between the study and control group [107]. 
 
 Zhang J study showed that increased chance of weight gain is seen in 
subclinical hypothyroidism Chinese adolescents[122]. 
 
6.6 Free T3, Free T4 
 No signifying difference between T3, T4 levels in control and study group. 
(p Value=0.844, pValue=0.023). p Value is statistically not significant for T3, T4 
Subclinical hypothyroidism T3, T4 levels are normal. 
 
6.7 Thyroid stimulating hormone 
 Thyroid stimulating hormone levels are elevated in subclinical 
hypothyroidism patients (p Value =0.000). p Value is statistically significant 
 
 
 
89 
 
 My present study shows that 22 persons have TSH value of >10mIU/L. 
About 8persons have TSH value between5.1mIU/L and 10mIU/L. 
 
 Hamilton et al reported the upper reference limit for TSH is 4.1 
mIU/L[123]. 
 
 Vahab reported that follow up should be given if TSH value is 3-5mIU/L 
with positive antithyroid antibodies[124]. 
 
6.8 Thyroglobulin antibody 
 In the present study, the analysis revealed that there is an increase in Anti-
Tg levels in subclinical hypothyroid patients. 
 
 Normal anti-Tg level is ( Harrison’s) <40IU/mL[125].  
 
 Hollowell,Surks MI et al reported that anti-thyroid antibodies levels are 
increased as age advances and is also associated with parallel increase in serum 
TSH levels. It is responsible for increased occurrence of acquired autoimmune 
thyroid disease [126,127]. 
 
6.9 Thyroid peroxidase antibody 
 My study shows that thyroid peroxidase antibody levels are increased in (p 
Value=0.000) subclinical hypothyroidism patients.  p Value is statistically 
significant. The same finding was explained by following authors.  
AnnemiekeRoos et al reported that positive relationship exists between the TPO-
Abs and TSH. Both of them predict the development of hypothyroid state 
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and“presence of TPOAbs necessitating a compensatory increase in levels of TSH 
for maintenance of euthyroidism, even in the euthyroid range” [128]. 
 
 Normal range in humans for anti-TPO (Harrison) <35IU/mL[125].  
 
 Vanderpump MP reported that presence of anti-TPO in subclinical 
hypothyroidism has increased chance of getting overt hypothyroidism later in life. 
 
 Thomas cyric reported that about 68.9% of subclinical hypothyroidism 
patients had positive TPO-Abs.  
 
 Thomas cyric and Ghoraishian SM explained that positive correlation 
exists between TSH and TPO-Abs. 
 
 Zois  andJaksi et al reported that all subclinical hypothyroid patients had 
positive anti-thyroid antibodies [129, 130]. 
 
 Controversy to my study was explained by Zimmermann. He reported that 
no relation exists between subclinical hypothyroid patients and anti-thyroid 
antibodies [131]. 
 
6.11 Lipid profile 
 The present study reveals that elevated levels of total cholesterol, low 
density lipoprotein and LDL/HDL ratio is seen subclinical hypothyroid patients. 
But triglycerides, HDL and TGL/HDL ratio are normal in my study. 
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 My study was supported by A. IQBAL et al. He revealed that serum TSH 
levels and Total Cholesterol and LDL-C levels are positively correlated. 
Thyroxine reduces these lipids levels [132]. 
 
 Azad reza et al reported that subclinical hypothyroidism was associated 
with dyslipedemia. 
 
 BeataAIneck et al reported that subclinical hypothyroidism has little 
effects on Triglycerides level and favours my study. 
 
 Miura et al reported similar findings like that of my study. They 
concluded that subclinical hypothyroidism associated with elevated levels of total 
cholesterol and LDL-cholesterol [3]. 
 
 Ph. Caron et al report does not support my study. He revealed that total 
cholesterol, triglycerides and apolipoprotein levels are normal in subclinical 
hypothyroidism patients[133]. 
 
 Kung et al reported that subclinical hypothyroidism patients had increased 
LDL- cholesterol and reduced HDL cholesterol [134]. 
 
 BeataAIneck et al reported that subclinical hypothyroidism leads to pro-
atherogenic lipid profile in patients with elevated TSH. Thyroxine treatment 
reduces the total cholesterol and low density lipoprotein but has no effects on 
triglycerides. Further studies needed to prove the effects on HDL and lipoprotein 
levels.  
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10. Brainstem evoked response audiometry-Earlier identification of 
neurological changes in subclinical hypothyroidism is done by using BERA. 
 
 Brainstem audiotory evoked potential evaluates the audiotory nerve, 
brainstem and subcortical structures by using audiotory stimulation. 
 
It is a simple,non invasive method to detect the abnormalities in neuronal 
pathway of hearing from inner ear to auditory cortex. 
 
 Kirti Sharma et al reported that hearing loss is seen in hypothyroidism 
and studies reveal that prolongation of both central and peripheral conduction 
time in hypothyroidism. Conductive, sensorineural and mixed type of hearing loss 
is seen. 
 
 Sangeetagupta et al strongly suggests that abnormal BERA waves are 
seen in subclinical hypothyroidism. He reported that prolongation of both absolute 
latency of waves and IPLs (III-V and I-V). 
 
 Sangeetagupta et al reported that some studies did not show any 
alternation in BERA in subclinical hypothyroidism. 
 
 Ozata M et al study reported that Abnormal BAEPs in subclinical 
hypothyroidism have not been reported. 
 
 Sharma K et al reported that prolongation of wave V latencies is seen in 
subclinical hypothyroidism. 
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 Figueiredo LC et al showed that prolongation of absolute latencies of 
waves III and V in the subclinical hyporhyroidism [135]. 
 
6.12. Interpretation of BERA waves 
 Wave I abnormality shows involvement of peripheral nervous system. 
Other waves reports that abnormal involvement of central nervous system.  
 
a.Wave-I 
Right ear p Value =0.968. p Value is statistically not significant. 
Left ear p Value =0. 693. pValue is statistically not significant. 
 My study reveals that no significant change in absolute latency of wave-I 
between subclinical hypothyroidism patients and control group in both ears. 
 
    It shows that absence of peripheral hearing impairment in subclinical 
hypothyroid patients. Kirit Sharma and Ozata et al reported the similar findings 
i.e there is absence of changes in brainstem auditory evoked potential in 
subclinical hypothyroid patients. 
 
 Sangeetagupta et al study reveals controversy findings in subclinical 
hypothyroid patients and reported that prolongation of absolute latency of wave 1 
in BERA. 
 
b. Wave II 
 The Present study shows that no change in absolute latency of wave II 
between control and study group in both ears 
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Right ear p Value =0. 788.  pValue is statistically not significant. 
Left ear p Value =0. 379. pValue is statistically not significant. 
 
c. Wave III 
 Absolute latency of wave III means onset of stimulus to peak of wave III. 
It is measured in milliseconds. It is normal in both ears. 
 
Right ear p Value =0. 463. pValue is statistically not significant. 
Left ear p Value =0. 532 .pValue is statistically not significant. 
 
 Kirit Sharma and Ozata et al reported the similar findings i. e there is 
absence of changes in brainstem auditory evoked potential in subclinical 
hypothyroid patients. 
 
 Sangeetagupta et al study reveals controversy findings to my study in 
subclinical hypothyroid patients and reported that prolongation of wave III in 
BERA. 
 
 Figueiredo LC et al concluded that prolongation of absolute latency of 
wave III in subclinical hypothyroid patients. 
 
d.Wave IV 
Right ear p Value =0. 815. pValue is statistically not significant. 
Left ear p Value =0. 425. pValue is statistically not significant. 
The Present study shows no significant changes in absolute latency of wave IV 
between control and study group in both ears.  
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e.Wave V 
Right ear p Value =0. 040. pValue is statistically significant. 
Left ear p Value =. 008. pValue is statistically  significant. 
 The present study shows that prolongation of absolute latency of Wave V 
in subclinical hypothyroid patients in both ears which means onset of stimulus to 
peak of wave V.  
 
 Kirit Sharma et al reported the similar findings i.e there is prolongation 
absolute latency of wave V in brainstem auditory evoked potential in subclinical 
hypothyroid patients in both ears. 
 
 Figueiredo LC et al concluded that prolongation of absolute latency of 
wave Vin subclinical hypothyroid patients. 
 
IPLI-III 
Right ear p Value =0. 483. pValue is statistically not significant. 
Left ear p Value =0. 810.pValue is statistically not significant. 
 Inter peak latencies I-III in the present study, reflects that there is no 
significant changes in both ears and conduction time between cochlea and caudal 
pons is normal. 
 
 Cristiane et al reported controversy findings to my study i.e increase in 
IPL I-III in subclinical hypothyroidism group in both ears. 
 
 Kirit Sharma and Ozata et al reported no specific changes in IPLI-III in 
both ears like my study. 
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f.Inter Peak Latency III-V 
Right ear p Value =0. 155. pValue is statistically not significant. 
Left ear p Value =0. 104. pValue is statistically not significant. 
 
 Inter peak latencies III -V in the present study is found to be normal in both 
ears. 
 
 Cristiane et al and SangeetaguPta et al reported controversy findings to 
my study i.e increase in IPL III-V in subclinical hypothyroidism group in both 
ears. 
 
g. Inter Peak Latency I-V 
Right ear p Value =0. 052. pValue is statistically not significant. 
Left ear p Value =0. 060. pValue is statistically not significant. 
Inter peak latencies I -V in the present study is found to be normal in both ears. 
 
 Cristiane et al, and SangeetaguPta et al reported controversy findings to 
my study i.e increase in IPL I-V in subclinical hypothyroidism group in both ears. 
 
6.13 Correlation  of variables 
 There was positive correlation between Anti-Tg and Anti-TPO in the both 
ear and negative correlation between total cholesterol and LDL values in both 
ears. 
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 Wojeiech et al reported that positive correlation present between anti-
thyroid peroxidase antibody levels in blood and changes in the central part of 
hearing organ[109]. 
 
 Aysearduc demonstrated that thyroid autoimmunity is responsible for 
reduced hearing ability[111]. 
 
 Ilhan reported that there is a correlation between increased levels of thyroid 
antibodies and BAEP parameter and it is related to autoimmue mediated 
mechanism[110]. 
 
 LeventRenda reported that atoimmune antibodies produces changes in 
inner ear it leads to sensorineural hearing loss. 
 
 First time Lehnardt explained about antigen antibody reaction was seen 
sensorineural hearing loss. 
 
 Antibodies act against inner ear structure like spiral ligament, 
striavascularis and supporting cells. The following autoimmue mechanism is 
involved like intolerance, cross-reactions and genetic factors. 
 
 LeventRenda study reported that circulating antithyroid antibodies is a 
cause for hearing impairment[111]. 
 
 My study shows that increased antibody levels produces changes in 
Brainstem evoked potential which is correlating with Wojeiech et al [109]. 
  
Conclusion 
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7. CONCLUSION 
Functional integrity of the central nervous system and hearing status is 
evaluated in newly diagnosed subclinical hypothyroid patients by brainstem 
evoked response audiometry. 
 
 The central nervous system is affected in subclinical hypothyroidism. It is 
expressed by an increase in the latency of BERA wave V in both ears.  Subclinical 
hypothyroidism leads to overt hypothyroidism. Early identification of thyroid 
hormone deficiency prevents further progression of disease and its related 
morbidity. Autoimmunity is the most probable factor for subclinical 
hypothyroidism. It is clearly shown by elevated levels of thyroid peroxidase 
antibody and thyrglobulin antibody. Elevated level of low density lipoprotein and 
total cholesterol is seen in patients with subclinical hypothyroidism. 
 
 Increased levels of antibody is the cause for changes in BERA, it leads to 
central nervous system dysfunction and hearing defects. It is clearly shown by 
positive correlation exists between thyroid antibodies BERA changes. Increased 
cholesterol may be a contributing factor. Thyroxine treatment may be given to 
prevent disease progression and hence central nervous system dysfunction and 
audiological dysfunction in earlier stages itself. 
 
Limitations of the study 
 However, the study has got its own limitation and a larger sample size is 
needed to confirm the findings. Further research is needed to confirm the 
correlation between thyroid antibodies and other waves and the inter peak latency 
of BERA. 
  
Summary 
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8. SUMMARY 
 Hypothyroidism is one of the important disorders of thyroid gland. Hearing 
defects are also common in hypothyroidism. Subclinical hypothyroidism is a 
clinical condition associated with elevated level of thyroid stimulating hormone 
with normal levels of thyroxine(T4) and triiodothyronine(T3 ) is present. 
Subcinical hypothyroidism becomes overt hypothyroidism. This study aimed to 
identify central nervous system dysfunction and hearing defects by using 
brainstem evoked response audiometry in subclinical hypothyroid patients. 
 
 30 newly diagnosed subclinical hypothyroid patients were selected, 
brainstem evoked response audiometry, thyroid peroxidase antibody and 
thyroglobulin antibody levels and lipid profile was done. All these procedure was 
done in control subject also. 
 
 My study shows that elevated level of thyroid peroxidase antibody and 
thyroglobuin antibody is present in patients with subclinical hypothyroidism. Also 
Low density lipoprotein and total cholesterol are increased in subclinical 
hypothyroidism patients. BERA results showed that V wave latency is increased 
in subclinical hypothyroidism patients. 
 
 BERA results showed that auditory pathway is affected in subclinical 
hypothyroidism due to defect in brain structure. Audiological impairment occurs 
along with central nervous system dysfunction. 
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 Autoimmunity is a cause for subclinical hypothyroidism, because elevated 
levels of antibody is present. The pathophysiological cause for hearing defects in 
hypothyroidism is deterioration of oxygenation and metabolism in the organ of 
corti and striavascularis. It leads to changes in protein synthesis, enzymes action 
and myelin production. Hyperlipidemia also leads to hearing impairment. 
 
 Increased level of thyroid antibodies is responsible for changes in 
brainstem evoked potential. 
 
 By using simple non-invasive method (BERA) we can identify central 
nervous system dysfunction at earlier stages in subclinical Hypothyroidism. 
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Annexures 
 
INFORMATION TO PARTICIPANTS 
 
Investigator: Dr. P. Senthamil pavai 
 
Name of Participant: 
 
Title:“Evaluation of effect of  brainstem evoked response audiometry in 
subclinical Hypothyroid patients in correlation with Thyroglobulin antibody, 
Thyroid peroxidase antibody and Lipid profile” 
 
 You are invited to take part in this research/ study /procedures. The 
information in this document is meant to help you decide whether or not to take 
part. Please feel free to ask if you have any queries or concerns. 
          You are being asked to participate in this study being conducted in 
Medical Endocrine clinic, Rajiv Gandhi Govt. General Hospital, Madras Medical 
College, Chennai – 3 and  Institute of  Physiology and Experimental Medicine, 
Madras Medical College, Chennai - 3. 
 
What is the Purpose of the Research? 
The purpose of this study is to evaluate the effectiveness of a BERA in early 
identification of hearing loss and CNS dysfunction in Subclinical Hypothyroidism 
patients by non-invasive method. 
  
The Study Design    -Case control study 
 
The Study Procedures: Blood investigation for Thyroglobulin antibody, 
Thyroid peroxidase antibody and Lipid profile”and BERA to rule out hearing 
and CNS dysfunction. 
 
Possible Risks to you - Nil 
 
Possible benefits to you- Earlier identification of hearing and CNS dysfunction 
due to Subclinical hypothyroidism by non invasive method. 
 
Possible benefits to other people:  
The result of the research may provide benefits to the society in terms of 
advancement of medical knowledge and/or therapeutic benefits to future patients.  
 
Confidentiality of the information obtained from you 
You have the right to confidentiality regarding the privacy of your medical 
information (personal details, results of physical examinations, investigations, and 
your medical history). By signing this document, you will be allowing the 
research team investigators, other study personnel, sponsors, IEC and any person 
or agency required by law like the Drug Controller General of India to view your 
data, if required. 
The information from this study, if published in scientific journals or presented at 
scientific meetings, will not reveal your identity. 
 
How will your decision do not participate in the study affect you? 
Your decisions of not participating in this research study will not affect your 
medical care or your relationship with investigator or the institution. Your doctor 
will still take care of you and you will not lose any benefits to which you are 
entitled. 
 
Can you decide to stop participating in the study once you start? 
The participation in this research is purely voluntary and you have the right to 
withdraw from this study at any time during course of the study without giving 
any reasons. However, it is advisable that you talk to the research team before 
stopping the treatment. 
  
INFORMED CONSENT FORM 
 
Title of the study  :  “Evaluation of effect of brainstem evoked response 
audiometry in subclinical Hypothyroid patients in correlation with 
Thyroglobulin antibody, Thyroid peroxidase antibody and Lipid profile 
 
Name of the Participant:  
 
Name of the Principal Investigator: Dr. P. SENTHAMIL PAVAI 
 
Name of the Institution: Institute of Physiology and Experimental Medicine, 
                                          Rajiv Gandhi Government General Hospital 
                                          Madras Medical College, 
                                          Chennai – 3 
 
 
Documentation of the informed consent 
I, _____________________________ have read the information in this form (or it 
has been read to me). I was free to ask any questions and they have been 
answered. I am over 18 years of age and, exercising my free power of choice, 
hereby give my consent to be included as a participant in 
 “Evaluation of effect of brainstem evoked response audiometry in 
subclinical Hypothyroid patients in correlation with Thyroglobulin antibody, 
Thyroid peroxidase antibody and Lipid profile” 
 
1.  I have read and understood this consent form and the information provided to 
me. 
2.  I have had the consent document explained to me. 
3.  I have been explained about the nature of the study. 
4.  I have been explained about my rights and responsibilities by the investigator. 
5.  I have been informed the investigator of all the treatments I am taking or have 
taken in the past ________ months including any native (alternative) 
treatment. 
6. I have been advised about the risks associated with my participation in this 
study. 
7. I agree to cooperate with the investigator and I will inform him/her immediately 
if I suffer unusual symptoms.  
8. I have not participated in any research study within the past _______month(s).  
9. I am aware of the fact that I can opt out of the study at any time without having 
to give any reason and this will not affect my future treatment in this hospital.  
10. I am also aware that the investigator may terminate my participation in the 
study at any time, for any reason, without my consent.  
12. I hereby give permission to the investigators to release the information 
obtained from me as result of participation in this study to the sponsors, 
regulatory authorities, Govt. agencies, and IEC. I understand that they are 
publicly presented. 
13. I have understand, that my identity will be kept confidential if my data are 
publicly presented. 
14. I have had my questions answered to my satisfaction. 
15. I have decided to be in the research study. 
I am aware that if I have any question during this study, I should contact the 
investigator. By signing this consent form, I attest that the information given in 
this document has been clearly explained to me and understood by me, I will be 
given a copy of this consent document. 
 
For adult participants: 
 
Name and signature / thumb impression of the participant (or legal 
representative if participant incompetent) 
 
Name ____________________ Signature_____________ Date___________ 
 
Name and Signature of impartial witness (required for illiterate patients): 
 
Name ____________________ Signature_____________ Date___________ 
 
Address and contact number of the impartial witness: 
 
Name and Signature of the investigator or his representative obtaining 
consent: 
 
Name ____________________ Signature_____________ Date___________ 
  
   
   
 
PROFORMA 
 
Name: 
Age/ Sex: 
Address: 
OP No.:   
Occupation: 
 
Duration of any non specific symptoms 
 
History of associated illness: 
a. Hypertension 
b. Ischemic heart disease 
c. Bronchial asthma  
d. Renal diseases 
 
Investigations: 
 
 
 
EXAMINATION 
General examination: 
Temperature: 
Pulse rate:  
Blood pressure:  
 
Examination of Thyroid: 
 
 
Systemic examination: 
Cardiovascular system: 
 
Respiratory system: 
 
Gastrointestinal system: 
 
Central nervous system: 
  
 
 
1. Serum Samples 
 
 
 
 
 
 
2.Anti-Tg and Anti-TPO 
 
 
 
  
 
 
3. ElectroChemiluminescence immunoassay 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
4. Recordings of brainstem evokedresponse audiometry 
 
 
 
 
CONTROL GROUP- THYROID PROFILE, ANTIBODY LEVELS & LIPID PROFIE 
S.NO AGE SEX HT (m) 
WT 
(kg) BMI 
T3 T4 TSH ANTI-Tg 
ANTI-
TPO 
Total 
Cholesterol HDL TGL VLDL LDL LDL/HDL TGL/HDL 
(pmol/L) (ngm/dl) (µIU/ml) (IU/ml) (IU/ml) (mg/dl) (mg/dl) mg/dl mg/dl mg/dl 
1 52 F 1.5 63 28 4.2 0.94 3 10.92 26.35 158 55 140 28 75 1 3 
2 43 F 1.72 68 23 3.2 0.96 4 10.45 47.04 184 58 140 28 98 2 2 
3 44 F 1.7 68 24 3.4 1.1 3.4 14.38 22.69 165 40 135 27 98 2 3 
4 60 F 1.52 63 27 5 1 4.2 15.33 84.51 185 55 150 30 100 2 3 
5 48 F 1.74 70 23 4.8 1.4 4.1 15.58 600 198 50 140 28 120 2 3 
6 55 F 1.68 60 21 6 1.6 3.2 10 12.57 183 56 150 30 97 2 3 
7 53 F 1.88 76 22 5.9 1 4.2 13.55 28.2 178 55 125 25 98 2 2 
8 49 F 1.76 72 23 5.4 1.6 3.7 50 293.3 178 54 140 28 96 2 3 
9 44 F 1.74 70 23 4.2 1 3 112.3 55 148 56 150 30 62 1 3 
10 26 F 1.65 60 22 4.4 0.99 4 10 13.39 188 60 150 30 98 2 3 
11 34 F 1.45 42 20 4 1.1 2.8 10.59 16.85 146 40 145 29 77 2 4 
12 48 F 1.47 50 23 3 1.2 3.1 119.5 47.26 170 54 150 30 86 2 3 
13 33 F 1.5 55 24 5.6 1.4 3 10 13.35 175 50 150 30 95 2 3 
14 36 F 1.48 40 18 5.4 1.7 2.9 10 8.43 178 56 145 29 93 2 3 
15 39 F 1.59 50 20 3.2 1.7 4 10 9.62 170 54 130 26 90 2 2 
16 40 F 1.78 64 20 3.4 1 4.2 10 115.1 168 40 140 28 100 3 4 
17 43 F 1.54 54 23 4 1.5 3.8 10 12.12 230 56 150 30 144 3 3 
18 45 F 1.74 66 22 4.6 1 3.6 13.47 12.78 174 58 120 24 92 2 2 
19 29 F 1.4 55 28 4.6 0.96 3.7 10 16.57 200 50 150 30 120 2 3 
20 30 F 1.75 62 20 5.2 1.3 4.1 10 13.11 198 56 150 30 112 2 3 
21 33 F 1.77 68 22 4 0.97 4.2 55 10.7 162 60 150 30 72 1 3 
22 32 F 1.62 60 23 3.4 1.2 3.4 43.42 24.08 180 56 150 30 94 2 3 
23 32 F 1.68 68 24 6 1.5 3.3 55 45 186 76 140 28 82 1 2 
24 55 F 1.55 50 21 5.4 1.4 4 104.9 24.3 170 42 150 30 98 2 4 
25 56 F 1.65 43 16 6 1 3 10 15.73 145 50 140 28 67 1 3 
26 32 F 1.58 51 20 3.6 1 2.8 11.46 13.35 148 40 150 30 78 2 4 
27 45 F 1.57 50 20 4.6 1.6 3.6 18.9 29.45 160 58 145 29 73 1 3 
28 43 M 1.65 48 18 4 1.3 3.2 10 14.76 160 50 150 30 80 2 3 
29 26 M 1.74 69 23 4.4 1.2 3.3 13.04 16.51 178 50 150 30 98 2 3 
30 40 M 1.77 73 23 5 1.2 3 82.23 24.94 178 52 135 27 99 2 3 
SUBCLINIAL HYPOTHYROIDISM - THYROID PROFILE,ANTIBODY LEVELS &LIPID PROFILE 
S.NO AGE SEX HT(m) WT(kg) BMI 
T3 T4 TSH ANTI-Tg ANTI-TPO 
Total 
cholesterol HDL TGL VLDL LDL LDL/HDL TGL/HDL 
pmol/l ngm/dl (µIU/ml) (IU/ml) (IU/ml) mg/dl mgm/dl mg/dl mg/dl mg/dl 
1 41 F 1.58 68 27 4.9 1.2 5.8 11.57 17.16 212 20 164 33 159 8 8 
2 52 F 1.56 63 26 4.6 1.2 17.9 120.2 11.12 204 53 103 21 130 2 2 
3 55 F 1.54 68 29 4.56 1.11 9.13 10 155 217 57 118 24 136 2 2 
4 46 F 1.49 58 26 2.3 1.4 15 396.5 250.1 249 34 314 63 152 4 9 
5 27 F 1.7 80 28 5.3 1.1 17 400 600 156 42 93 19 95 2 2 
6 20 F 1.58 54 22 4.3 1.1 12.8 170.3 593 208 47 221 44 117 2 5 
7 30 F 1.58 68 27 2.49 0.98 16.98 190 243.2 148 43 116 23 82 2 3 
8 22 F 1.62 64 24 5.4 1.2 6.6 102.6 668 154 62 85 17 75 1 1 
9 45 F 1.35 50 27 4 1.4 22.47 400 322 155 40 70 14 101 3 2 
10 43 F 1.68 79 28 4 1.4 10.49 145 14.2 136 46 106 21 69 1 2 
11 40 F 1.5 92 41 5.3 1.1 6.4 185.7 600 266 50 102 20 196 4 2 
12 36 F 1.78 73 23 4.8 1 13.4 69.2 600 210 13 124 25 172 13 10 
13 44 F 1.75 76 25 4.4 1.2 26.8 400 8.99 212 91 250 50 71 1 3 
14 43 F 1.6 54 21 4.6 1.2 14.31 221.7 372.7 124 28 169 34 62 2 6 
15 27 F 1.56 78 32 4.6 1 11 10 7.9 134 37 110 22 75 2 3 
16 32 F 1.48 75 34 5.3 1 16.8 19 81.53 255 44 102 20 191 4 2 
17 47 F 1.58 68 27 4.4 1 7.57 120.2 138.2 221 48 405 81 92 2 8 
18 55 F 1.58 63 25 5 1.1 12 432.5 600 215 59 135 27 129 2 2 
19 27 F 1.7 88 30 4.7 1 16.4 123 600 220 46 171 34 140 3 4 
20 24 F 1.64 68 25 4 1 14.88 401.1 421.7 161 42 123 25 94 2 3 
21 28 F 1.62 70 27 4.4 1.2 15.12 319.6 23.3 221 64 156 31 126 2 2 
22 24 F 1.62 58 22 5.5 0.9 13.2 92.36 250 226 36 183 37 153 4 5 
23 27 F 1.68 69 24 4.4 1 6.34 150 596.5 273 34 330 66 173 5 10 
24 31 F 1.36 58 31 4.5 1.2 16 57.89 309.6 258 47 171 34 177 4 4 
25 24 F 1.78 80 25 5.3 0.98 17.6 10 115.3 230 64 100 20 146 2 2 
26 20 F 1.58 68 27 5 1.1 17.7 467.7 600 142 51 73 15 76 1 1 
27 36 F 1.58 83 33 3.05 0.98 7.63 257.7 230 165 58 122 24 83 1 2 
28 42 M 1.48 68 31 4.7 0.98 5.7 61.83 600 156 44 93 19 93 2 2 
29 29 M 1.6 70 27 4.8 1.1 10 123.4 61.32 250 64 78 16 170 3 1 
30 44 M 1.68 78 28 4 1 12 10.1 600 260 47 94 19 194 4 2 
BRAINSTEM EVOKED RESPONSE AUDIOMETRY -CONTROL GROUP 
Right Ear Left Ear 
S.NO wave I Wave II Wave III Wave IV Wave V IPL I-III IPL III-V IPL I-V Wave I Wave II Wave III Wave IV Wave V IPL I-III IPL III-V IPL I-V 
1 1.63 2.84 3.65 4.8 5.61 2.02 1.96 3.98 1.53 2.83 3.85 4.87 5.6 2.32 1.75 4.07 
2 1.67 2.89 3.81 4.8 5.72 2.14 1.91 4.05 1.55 2.8 3.68 4.86 5.9 2.13 2.22 4.35 
3 1.68 2.78 3.86 4.88 5.73 2.18 1.87 4.05 1.6 2.81 3.62 4.81 5.8 2.02 2.18 4.2 
4 1.76 2.68 3.94 4.89 5.56 2.18 1.62 3.8 1.51 2.91 3.9 4.88 5.6 2.39 1.7 4.09 
5 1.66 2.79 3.87 4.76 5.79 2.21 1.92 4.13 1.52 2.67 3.55 4.79 5.54 2.03 1.99 4.02 
6 1.59 2.68 3.97 4.9 5.73 2.38 1.76 4.14 1.55 2.78 3.56 4.68 5.6 2.01 2.04 4.05 
7 1.62 2.83 3.64 4.67 5.6 2.02 1.96 3.98 1.57 2.77 3.5 4.97 5.59 1.93 2.09 4.02 
8 1.7 2.78 3.67 4.68 5.55 1.97 1.88 3.85 1.7 2.89 3.44 4.69 5.9 1.74 2.46 4.2 
9 1.94 2.78 3.67 4.9 5.53 1.73 1.86 3.59 1.64 2.68 3.79 4.8 5.57 2.15 1.78 3.93 
10 1.65 2.67 3.4 4.88 5.65 1.75 2.25 4 1.88 2.71 3.9 4.78 5.55 2.02 1.65 3.67 
11 1.64 2.69 3.68 4.79 5.7 2.04 2.02 4.06 1.77 2.69 3.98 4.45 5.6 2.21 1.62 3.83 
12 1.65 2.78 3.65 4.9 5.6 2 1.95 3.95 1.54 2.9 3.98 4.99 5.8 2.44 1.82 4.26 
13 1.66 2.8 3.5 4.9 5.6 1.84 2.1 3.94 1.78 2.55 3.55 4.6 5.7 1.77 2.15 3.92 
14 1.65 2.75 3.4 4.9 5.61 1.75 2.21 3.96 1.55 2.42 3.8 4.97 5.7 2.25 1.9 4.15 
15 1.68 2.77 3.77 4.75 6.2 2.09 2.43 4.52 1.99 2.83 3.69 4.55 5.54 1.7 1.85 3.55 
16 1.6 2.63 3.6 4.8 5.6 2 2 4 1.4 2.55 3.5 4.5 5.6 2.1 2.1 4.2 
17 1.7 2.67 3.73 4.73 5.6 2.03 1.87 3.9 1.87 2.85 3.9 4.8 5.54 2.03 1.64 3.67 
18 1.63 2.68 3.64 4.86 5.62 2.01 1.98 3.99 1.88 2.73 3.79 4.69 5.67 1.91 1.88 3.79 
19 1.62 2.78 3.6 4.9 5.77 1.98 2.17 4.15 1.57 2.74 3.7 4.99 5.5 2.13 1.8 3.93 
20 1.77 2.9 3.7 4.88 5.3 1.93 1.6 3.53 1.46 2.5 3.34 4.3 5.6 1.88 2.26 4.14 
21 1.64 2.85 3.4 4.76 5.6 1.76 2.2 3.96 1.48 2.47 3.6 4.88 5.68 2.12 2.08 4.2 
22 1.65 2.7 3.5 4.97 5.67 1.85 2.17 4.02 1.8 2.7 3.75 4.75 5.7 1.95 1.95 3.9 
23 2 2.7 3.76 4.97 5.7 1.76 1.94 3.7 1.98 2.99 3.7 4.88 5.6 1.72 1.9 3.62 
24 1.68 2.7 3.73 4.74 5.6 2.05 1.87 3.92 1.43 2.99 3.99 4.99 5.58 2.56 1.59 4.15 
25 1.59 2.8 3.55 4.89 5.59 1.96 2.04 4 1.42 2.42 3.44 4.44 5.69 2.02 2.25 4.27 
26 1.61 2.7 3.79 4.88 6.1 2.18 2.31 4.49 1.65 2.9 3.3 4.3 5.6 1.65 2.3 3.95 
27 2 2.75 3.65 4.68 5.62 1.65 1.97 3.62 1.8 2.75 3.9 4.77 5.21 2.1 1.31 3.41 
28 1.78 2.68 3.65 4.68 5.63 1.87 1.98 3.85 1.7 2.3 3.88 4.41 5.55 2.18 1.67 3.85 
29 1.6 2.76 3.73 4.94 5.8 2.13 2.07 4.2 1.9 2.65 3.89 4.88 5.54 1.99 1.65 3.64 
30 1.67 2.78 3.55 4.88 5.8 1.88 2.25 4.13 1.53 2.63 3.88 4.99 5.7 2.35 1.82 4.17 
 BRAINSTEM EVOKED RESPONSE AUDIOMETRY -STUDY GROUP 
Right Ear Left Ear 
S.No Wave I Wave II Wave III Wave IV Wave V IPL I-III IPL III-V IPL I-V Wave I Wave II Wave III Wave IV Wave V IPL-I-III IPL III-V IPL I-V 
1 1.75 2.65 3.45 4.9 5.35 1.7 1.9 3.6 1.88 2.99 3.58 4.55 5.9 1.7 2.32 4.02 
2 1.74 2.67 3.84 4.7 5.88 2.1 2.04 4.14 1.89 2.68 3.8 4.99 5.2 1.91 1.4 3.31 
3 1.78 2.69 3.89 4.89 5.89 2.11 2 4.11 1.87 2.55 3.8 4.8 5.9 1.93 2.1 4.03 
4 1.66 2.77 3.72 4.71 5.9 2.06 2.18 4.24 1.6 2.44 3.41 4.4 5.8 1.81 2.39 4.2 
5 1.87 2.8 3.71 4.91 5.91 1.84 2.2 4.04 1.48 2.48 3.4 4.3 5.8 1.92 2.4 4.32 
6 1.79 2.7 3.86 4.92 5.93 2.07 2.07 4.14 1.5 2.5 3.5 4.56 5.9 2 2.4 4.4 
7 1.7 2.8 3.7 4.99 5.98 2 2.28 4.28 1.3 2.98 3.6 4.96 5.8 2.3 2.2 4.5 
8 1.65 2.77 3.74 4.9 6.2 2.09 2.46 4.55 1.78 2.96 3.99 4.87 5.78 2.21 1.79 4 
9 1.65 2.78 3.55 4.8 5.88 1.9 2.33 4.23 1.7 2.9 3.98 4.97 5.86 2.28 1.88 4.16 
10 1.7 2.77 3.65 4.9 5.9 1.95 2.25 4.2 1.9 2.93 3.96 4.99 6.3 2.06 2.34 4.4 
11 1.76 2.78 3.88 4.79 5.91 2.12 2.03 4.15 1.89 2.91 3.96 4.8 5.89 2.07 1.93 4 
12 1.7 2.8 3.5 4.9 5.92 1.8 2.42 4.22 1.87 2.93 3.6 4.7 5.3 1.73 1.7 3.43 
13 1.7 2.82 3.87 4.87 6.2 2.17 2.33 4.5 1.85 2.94 3.89 4.68 5.89 2.04 2 4.04 
14 1.68 2.77 3.76 4.85 5.95 2.08 2.19 4.27 1.89 2.93 4.1 4.98 5.8 2.21 1.7 3.91 
15 1.74 2.77 3.76 4.75 5.2 2.02 1.44 3.46 1.3 2.95 3.97 4.55 5.77 2.67 1.8 4.47 
16 1.65 2.65 3.33 4.8 5.3 1.68 1.97 3.65 1.65 2.88 3.55 4.5 5.2 1.9 1.65 3.55 
17 1.68 2.79 3.85 4.79 5.7 2.17 1.85 4.02 1.88 2.89 3.6 4.5 5.9 1.72 2.3 4.02 
18 1.69 2.78 3.65 4.8 5.7 1.96 2.05 4.01 1.68 2.55 3.88 4.78 6.12 2.2 2.24 4.44 
19 1.66 2.78 3.58 4.91 6.1 1.92 2.52 4.44 1.99 2.58 3.92 4.99 5.88 1.93 1.96 3.89 
20 1.78 2.77 3.99 4.9 5.89 2.21 1.9 4.11 1.55 2.5 3.76 4.98 5.78 2.21 2.02 4.23 
21 1.63 2.71 3.78 4.78 5.4 2.15 1.62 3.77 1.44 2.79 3.55 4.99 6.3 2.11 2.75 4.86 
22 1.55 2.8 3.5 4.76 6.3 1.95 2.8 4.75 1.5 2.75 3.99 4.97 5.9 2.49 1.91 4.4 
23 1.65 2.8 3.75 4.74 5.8 2.1 2.05 4.15 1.45 2.78 3.83 4.99 5.6 2.38 1.77 4.15 
24 1.6 2.88 3.71 4.89 5.86 2.11 2.15 4.26 1.68 2.56 3.4 4.4 5.6 1.72 2.2 3.92 
25 1.54 2.77 3.87 4.8 5.2 2.33 1.33 3.66 1.67 2.74 3.83 5.1 5.9 2.16 2.07 4.23 
26 1.7 2.75 3.79 4.76 5.8 2.09 2.01 4.1 1.4 2.4 3.2 4.99 5.92 1.8 2.72 4.52 
27 1.67 2.76 3.78 4.96 5.91 2.11 2.13 4.24 1.54 2.8 3.75 4.5 5.34 2.21 1.59 3.8 
28 1.77 2.75 3.6 4.8 5.8 1.83 2.2 4.03 1.8 2.88 3.88 4.9 6.2 2.08 2.32 4.4 
29 1.73 2.65 3.3 4.8 6 1.57 2.7 4.27 1.33 2.89 3.8 4.99 5.2 2.47 1.4 3.87 
30 1.52 2.74 3.6 4.84 5.3 2.08 1.7 3.78 1.88 2.6 3.9 4.96 5.95 2.02 2.05 4.07 
